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PREFACE 
 
The thesis contains the results of the clinical researches carried out during my three 
years of PhD training. 
 
Chapter 1 is a brief introduction of the main field of my research, minimally invasive 
percutaneous thermal ablation of benign thyroid nodules by means of radiofrequency 
and laser sources. 
Chapter 2 to 6 report clinical researches in the field of percutaneous thermal ablation 
of benign thyroid nodules. 
Chapter 2 describes our experience in thermal ablation of benign thyroid nodule with 
 radiofrequency. 
Chapter 3 describes our experience in thermal ablation of benign thyroid nodule with 
laser. 
Chapter 4 illustrates a multicenter study of comparison of radiofrequency and laser 
ablation of benign thyroid nodule that involved some italian centers that perform 
minimally invasive procedures on thyroid. 
Chapter 5 documents a rare adverse events of radiofrequency ablation. 
Chapter 6 reports a case of a thyroid nodule that didn’t respond to radiofrequency 
ablation and that responded to laser ablation. 
Chapter 7 report clinical researches in other fields like primary hyperparathyroidism. 
All this works are published on indexed journals or in course of revision in indexed 
journals.  
  
CHAPTER 1  
Introduction 
 
In 2010 and in 2015 AACE-AME-ETA guidelines recommended  mini-invasive thermal 
ablation as possible terapeutical choice for benign thyroid nodules in patients that 
refuse thyroidectomy or that have comorbilities that contraindicated surgery [1, 2]. 
These techniques arrived in Italy in the last 10 years, thus in 2015 the Italian opinion 
statement was written [3]. 
Not-invasive techniques as TSH suppression with levo-tiroxine in the euthyroid patient 
could reduce the nodule growth and prevent new nodules formation[4], but many 
evidences suggest that this treatment in efficient just in single solid nodules; only 20% 
of nodules reduces significantly in volume (>50%) and it often regrowth after L-T4 
suspension [5].   
Other possibility is radioiodine therapy after recombinant TSH, that reduces goiter 
volume from 35 to 56% but causes hypothyroidism in majority of patients [6]. 
The basic principle of  minimally invasive techniques on benign thyroid nodules, by 
mean of laser ablation (PLA) or radiofrequency ablation (RFA), is to create a thermal 
damage to the nodules resulting in an irreversible coagulative necrosis. Temperatures 
between 60-100C create irreversible tissue damage, temperatures above 100-110C 
result in carbonization which reduces the effectiveness of the procedure [7].  
Other minimally invasive thyroid nodule procedures include percutaneous 
alcoholization that was initially used in benign solid nodules, but now is the first choice 
in the treatment of recurrent cystic nodules [1, 2]. The success of alcoholization 
  
(volume reduction> 50%) is high (about 83%) and it improves neck symptoms in 78% of 
patients and benefit persists at least 24 months after the procedure [8]. For cystic 
nodules other minimally invasive techniques are to be considered in case of regrowth 
after alcoholization [3].  
In agreement with the Korean Society of Thyroid Radiology Consensus [7], laboratory 
tests (thyroid function and autoimmunity and calcitonin) should be evaluated before 
the procedures; morphology and cytology of the nodule (at least twice), cordal and 
heart functional state.  
These data are necessary to identify the correct indications to the procedure and to 
avoid possible adverse events [7]. In particular, if anti-thyroid antibodies are positive, 
the patient should be informed of the increased risk of hypothyroidism after RFA [7]. 
Before the procedure it’s necessary to suspend antiplatelet and anticoagulants [7]. The 
patient should be informed of the possibility of repetition of the procedure in a second 
time [7]. 
The RFA is started with a power of 30-50 W and increased by 10 W if an echogenic 
zone is not formed near the electrode tip after 5-10 seconds, up to a maximum power 
of 80-120 W. The power is reduced or the generator is switched off for a few seconds if 
the patient complains pain [9]. The electrode should be well visualized with US scan 
throughout its length and throughout the procedure to exclude damage to the "danger 
triangle" (recurrent laryngeal nerve, trachea and esophagus). The electrode should be 
placed in the deepest and most distant region of the nodule and then moved back to 
the most superficial and close to exclude visual disturbances due to echogenic bubbles 
  
[9, 10]. There is the possibility of using a "virtual track" system to visualize the tip of 
the electrode even when the tip is obscured by vapor bubbles [11].  
PLA is performed by inserting into the nodule, under ultrasound guidance, one or more 
optical fibers of 300 μm in diameter through some guides of 16-21 gauge diameter. 
The fibers then form an ellipsoidal shape which covers most of the area of the nodule. 
The patient is placed on an operating table in a supine position with the neck 
hyperextended [10]. 
The guides are inserted in cranio-caudal section. The energy is supplied at 1200-1800 
J/fiber starting at 1 cm from the bottom of the lesion. From the vaporization result an 
ecogenic area that increases in size. It is possible to perform one to two pull-backs of 1 
cm. The number of fibers, of pull-back, of released energy are evaluated according to 
the size of the nodule and the shape. The duration varies from 6 to 30 minutes and 
depends on the size. The generator must be switched off in case of pain, cough or the 
occurrence of adverse events [10]. 
In PLA and in RFA complications are rare (3-5%) and may be [10, 12]: 
- pain (most common) which decreases rapidly when the generator is turned off; it can 
persist even after the end of the procedure and is treated with analgesics; 
- changes in the tone of the voice, which may be due to a recurrent laryngeal nerve 
injury; 
- hematoma, which can be controlled with a compressive bendage; 
- skin burn, generally of first grade; treated with application of ice on the electrode 
insertion site; 
  
- rupture of the nodule, secondary to sudden expansion due to haemorrhage, treated 
with antibiotics and analgesics or with surgery in case of abscess; 
- transient thyrotoxicosis, which usually normalizes after one month, which can be 
treated with steroids; 
- hypothyroidism, more frequent in patients with functioning thyroid nodules or in in 
patients with positive autoimmunity. 
The cost of minimally invasive procedures is lower of a total thyroidectomy and of a 
hemithyroidectomy; the cost of a radiofrequency generator is about 25,000 dollars 
(often it is given in free loan); the cost of electrodes is 750 dollars per session. The 
average time of the procedure is about 30 minutes [13]. An Italian study compares the 
efficacy, tolerability and cost of RFA and hemithyroidectomy:  the cost for a session of 
RFA was 1661.5 euro, the cost of a hospitalization for hemithyroidectomy was 4139.4 
euro and for a short hospitalization (< 24h) [14]. The cost for an ultrasound equipment 
with laser source to perform PLA is high (about 120,000 dollars), but the cost of fibers 
per session are low (about $ 400); the treatment can be practiced as a day-hospital in 
30 minutes.  
After PLA, an intranodular cavitation confined by carbonized tissue can be seen few 
weeks after procedure. After few weeks a not vascularized hypoechoic area, 
compatible with the area of necrosis, with much more regular margins than the RFA 
can be seen at US scan. Consistency with qualitative elastosonography increases 
proportionally to fibrosis [15]. 
After the RFA the nodular tissue changes ultrasonographic characteristics and may 
erroneously appear with suspicious characteristics. Immediately after the procedure 
  
the released gas makes the nodule less evaluable. In RFA, carbonization of the tissue is 
a rare event; in that case the nodules appear more homogeneous and the margins of 
the necrotic area can be irregular. Consistency with qualitative elastosonography 
increases proportionally to fibrosis [15]. 
Analysis of the operative samples after thyroidectomy in nodules subjected to PLA 
showed the presence of necrosis, fibrotic degeneration without extrathyroid damage 
or cervical fibrosis [16]. 
Microwave and ultrasound ablations is less used and not yet approved by international 
guidelines [17, 18]. 
  
 
  
 
 
  
Primary hyperparathyroidism (PHPT) is a disorder characterized by inappropriately 
high secretion of parathyroid hormone (PTH). PHPT has become a common disease, 
with an estimated prevalence of 1% of the general population and 3% in 
postmenopausal women [19], and an increasing incidence over the last few decades. 
PHPT is usually the result of a single over-active parathyroid gland as a result of 
adenoma, hyperplasia or cancer [20]. The clinical presentation has changed over the 
years: today, 80–85% of cases are asymptomatic [21]. 
A National Institutes of Health consensus panel has recognized two forms of the 
disease: asymptomatic and symptomatic [22]. The diagnosis is based on the clinical 
and objective picture, evaluation of serum calcium (S-Ca) and PTH. Preoperative 
localization studies are required. 
Therapy may involve medical or surgical treatment, and many guidelines have been 
proposed over the years. Although parathyroidectomy (PTX) is regarded as the 
treatment of choice for patients with symptomatic hypercalcaemia or evidence of 
target organ damage [23], conservative management has been favored in 
asymptomatic patients. In addition, in some cases surgery fails, in some it is 
contraindicated, and in others it is refused [24]. At the most recent International 
Workshop [25], the guidelines pointed out that there was no data to support the 
medical treatment of patients with mild PHPT. In general, it is recommended that 
patients who do not meet surgical criteria [25] be monitored closely. However, the 
validity of medical treatment is unanimously recognised.  
The decision to employ a pharmacological approach depends also upon the goal of 
treatment, to reduce the serum calcium level and/or to increase BMD [26].  
  
Cinacalcet hydrochloride is a calcimimetic agent that binds to the calcium-sensing 
receptor (CaR) of parathyroid cells, resulting in diminished S-Ca, but has only a modest 
effect to reduce the PTH level and BMD does not change. Cinacalcet is generally well-
tolerated. The most common side effect is dose dependent and is nausea [27].  
Data from randomized controlled studies have consistently demonstrated that oral 
alendronate decreases bone turnover and increases BMD in patients with mild PHPT, 
although the effects on serum calcium PTH have been inconsistent [26]. 
Moreover, for most drugs, long-term data are insufficient regarding benefit and safety. 
There are limited data on the combination of bisphosphonate and cinacalcet in PHPT. 
The use of any of these pharmacological agents should be dictated by the goal. To 
increase BMD, bisphosphonate therapy would be the choice. If there is concern about 
the level of the serum calcium concentration, cinacalcet would be the choice to reduce 
it. If there is no intention to improve the BMD or to lower the serum calcium 
concentration, pharmacological agents are not used [25]. 
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CHAPTER 2:  
Quality of life in patients treated with radiofrequency ablation for thyroid nodules.  
Oddo S, Felix E, Repetto A, Mussap M, Giusti M.  
Res J Endocrinol Metab. 2016; 4: 1 
 
Background 
The greater availability of diagnostic techniques, together with an increase in attention 
to thyroid diseases, has led to a significant rise in diagnoses of thyroid cancer [1]. 
Consequently, the number of thyroidectomies for malignant disease is destined to 
grow. It is therefore essential to use minimally invasive techniques, such as thyroid 
radiofrequency ablation (RFA), in order to reduce the number of surgical procedures 
for benign diseases. Percutaneous thyroid RFA procedures are less expensive than 
thyroidectomy, whether total or partial, do not require hospitalization and cause only 
mild and rare adverse events. Moreover, they can be undertaken in patients with 
contraindications for surgery due to comorbidities. 
Since 2010, the AACE-AME-ETA guidelines have recommended thyroid RFA as a 
possible therapeutic option for the treatment of benign thyroid nodules [2]. 
Indications for RFA in thyroid nodules are: symptomatic benign disease (discomfort or 
pain in the neck, dysphagia, foreign body sensation, coughing or discomfort), aesthetic 
problems or autonomous functioning nodules [3]. Thyroid RFA can also be used to 
treat autonomous nodules if radiometabolic therapy is refused or not practicable [2]. 
For cystic nodules, mini-invasive therapy is considered in the case of regrowth after 
percutaneous ethanol ablation [3]. 
  
While many studies have reported reductions in treated nodules and improvements in 
the sense of pressure and aesthetic symptoms [4], only one study has described 
changes in quality of life (QoL). 
The aim of our study was to evaluate QoL changes in a cohort of patients treated with 
RFA for benign thyroid nodules from 2012 to 2015 in our department. QoL was 
monitored by means of a 13-scale questionnaire validated for thyroid diseases, namely 
Thyroid-specific Patient Reported Outcome (ThyPRO) [5]. Moreover, we assessed the 
efficacy of the procedure in correlation with certain features of the treated nodules 
and of patients, and recorded the frequency of adverse events and improvement in 
neck discomfort. 
 
  
Materials and methods 
 
Subjects 
From January 2012 to March 2015, patients with a benign thyroid nodule or a single 
predominant benign thyroid nodule (> 30 mm in diameter) in the context of a multi-
nodular goitre were evaluated in our department with a view to undergoing 
percutaneous thyroid RFA. These patients had either refused total or subtotal 
thyroidectomy or had comorbidities that contraindicated surgery. All patients signed 
an informed consent form that included a detailed explanation of the procedure and 
its purpose. The study was performed in compliance with the Helsinki Declaration and 
was approved by University of Genoa Ethics Committee. 
From January 2012 to March 2014, we enrolled 32 patients (24 females and 8 males) 
aged between 36 and 80 years (mean 56 ± 14 years) with a single thyroid nodule or a 
predominant thyroid nodule (> 30 mm in diameter) in a multi-nodular goitre; 11 
patients (34%) had a single nodule, while 21 (66%) had a prevalent nodule (> 30 mm in 
diameter) in the context of a goitre. These nodules, which had been discovered 9±11 
years earlier, were located in the right lobe in 13 patients (41%), in the left lobe in 18 
patients (56%) and in the isthmus in 1 patient (3%). Two patients had undergone 
ethanol ablation of the nodule approximately one year earlier, without significant 
benefit. One patient had undergone radioiodine therapy, without apparent benefit. 
Seven patients were on L-T4 replacement therapy for hypothyroidism at a mean dose 
of 329±156 mcg/week. Another patient was taking methimazole (2.5 mg/day) for a 
pre-toxic goitre, which displayed no hot areas on scintigraphy. 
  
After retrospective subdivision of patients into two groups (n=16 each group), no 
differences were observed in terms of sex, age, BMI, time since diagnosis, functional 
status of thyroid, nodule volume on enrolment, Joules administered during thyroid 
RFA, symptomatic visual analogic scale (VAS) (table 1) or ThyPRO score (table 2). 
Protocol 
To perform thyroid RFA, we followed the indications of the Consensus Statement of 
the Korean Society of Thyroid Radiology [3]. Before procedures, patients underwent 
complete anamnesis and physical examination, routine blood tests and thyroid 
function tests (f-T3, f-T4, TSH), evaluation of thyroid autoimmunity, calcitonin and 
thyroglobulin, ECG and phoniatric examination.  
The volume (ml) of the nodule undergoing thyroid RFA was evaluated by means of the 
ellipsoid formula: antero-posterior diameter x latero-lateral diameter x cranio-caudal 
diameter x 0.52 /1000. This formula was also used to calculate the total volume of 
each thyroid lobe [6]. 
Before thyroid RFA, patients underwent FNAB cytology on the nodule on two separate 
occasions, to confirm benignity (Thy 2 in accordance with the British Thyroid 
Association [7]). Only patients with a finding of benignity on both occasions underwent 
thyroid RFA. 
Patients filled out both a VAS that rated neck discomfort and a 13-scale Thyroid-
specific Patient Reported Outcome (ThyPRO) QoL questionnaire validated for patients 
with thyroid disease [5]. 
Clinical examinations, assessments of thyroid function and thyroid autoimmunity and 
VAS evaluation were repeated after 1 week and 1, 3 and 6 months, and then annually. 
  
ThyPRO and ultrasound thyroid volume were evaluated after 1, 3 and 6 months, and 
then annually. Phoniatric examination was repeated if symptoms related to chordal 
dysmotility appeared after the procedure.  
Subsequently, according to the percentage reduction of the treated nodule at the last 
evaluation, patients were divided into two groups: those with ≥30% reduction (group 
1) and those with <30% reduction (group 2). We looked for possible correlations 
between the degree of nodule reduction and some parameters: baseline volume 
nodule, Joules administered during thyroid RFA, time since diagnosis, hormonal status 
(TSH, f-T3, f-T4, thyroglobulin on enrolment and 1 week after the procedure) and 
patient age. The value of 30% was chosen in accordance with the mean percentage of 
nodule volume reduction recorded in our centre. 
 
Procedures 
Procedures were carried out in a day-hospital regimen. Antiplatelet and anticoagulant 
therapies were suspended for an appropriate time before the procedure. On the day 
of the procedure, patients were in a fasting state. After placement of a venous 
catheter, patients underwent intravenous infusion of ketorolac (20 mg) and ranitidine 
(50 mg) diluted in 100 ml of 0.9% saline solution for 30 minutes. Subsequently, 
intravenous ketorolac (40 mg) and ranitidine (50 mg) were administered in 500 ml of 
0.9% saline for about 5 hours (during and after thyroid RFA). In subjects allergic to 
ketorolac or in patients with moderate-to-severe renal impairment, premedication 
with intravenous paracetamol (500 mg) was carried out before and during the 
procedure. After thyroid RFA, a compressive bandage and ice were applied to the 
  
neck. Patients were allowed a light meal before being discharged in the early 
afternoon. All subjects received a domiciliary prescription for steroid administration 
(prednisone 25 mg for 3 days, 12.5 mg for 3 days, 6.25 for 3 days) and gastric 
protection, if not already ongoing. 
 
Methods 
Thyroid RFA was performed by means of 7 cm, 18 Gauge electrodes with a 1 cm active 
tip  (Starmed, Seoul, Korea). Procedures were performed with the support of an 
ultrasound echo-Laser XVG (Esaote, Genoa, Italy) with a 7.5 MHz linear probe (LA523).  
Follow-up ultrasound examinations were performed by means of a MyLab Five 
(Esaote, Genoa, Italy) ultrasound scanner with a 7.5 MHz linear probe (LA523) (Esaote, 
Genoa, Italy). 
The radiofrequency generator used was an RF System Viva VRS01 (Starmed, Seoul, 
Korea). The peristaltic pump was an R4S100 (Starmed, Seoul, Korea). 
Thyroid RFA was performed in a single session by a single operator with 3 years' 
experience by means of a moving-shot technique and trans-isthmic access.  
 
Laboratory tests 
TSH, f-T3 and f-T4 were measured by means of ultra-sensitive chemiluminescence 
immunoassay (Cobas® e602, Roche Diagnostics, Milan, Italy). The normal ranges are: 
0.27-4.2 mIU/L for TSH, and 2.76-7.07 pmol/L and 11.97-21.88 pmol/L for f-T3 and f-
T4, respectively. TPOAb and TgAb were evaluated by means of DiaSorin (Saluggia, 
Italy), concentrations <100 mU/L being regarded as negative. Calcitonin was measured 
  
by chemiluminescence immunoassay (DiaSorin); in our laboratory the normal value is 
<10 ng/L. Automated complete blood counts were taken by an ADVIA 2120 automated 
counter (Siemens Healthcare, Milan, Italy); coagulation tests were performed by 
means of an automated BCS analyzer (Siemens Healthcare, Milan, Italy), and 
biochemical tests for the routine assessment of hepatic and renal function on the fully-
automated Cobas® c701 platform (Roche Diagnostics, Milan, Italy). 
 
Questionnaires 
The subjective benefits of thyroid RFA were evaluated several times during the study 
by means of a VAS questionnaire with a score ranging from 0 (no 
symptoms/discomfort) to 10 (highest level of symptoms/discomfort). 
QoL was assessed before the procedure, after 1, 3 and 6 months and then annually, by 
means of ThyPRO, a validated questionnaire for thyroid diseases which consists of 13 
scales with multiple-choice answers (0 =  “none”; 1 = “slight”; 2 = “moderate”; 3 = 
“severe”; 4 = “very severe”). The ThyPRO scales concern the following aspects: goitre 
symptoms, hyperthyroid symptoms, hypothyroid symptoms, eye symptoms, tiredness, 
cognitive problems, anxiety, depressivity, emotional susceptibility, impaired social life, 
impaired daily life, impaired sexlife, cosmetic complaints. 
We also evaluate a further scale, present in the questionnaire that answer to the 
question “in the last 4 weeks thyroid disease has had a negative effect on your quality 
of his life?”, that we call “general score”. Lastly we consider also the mean values of 
13-scales score. 
 
  
Statistical analysis 
All data were analysed by means of GraphPad Prism for Windows (Version 6.0, 
GraphPad Software, San Diego, CA, USA). The data are presented as means ± SD, 
unless otherwise indicated. Continuous data were compared by means of the Mann-
Whitney test, while percentages were compared by means of the Fisher test. 
Correlations between variables were assessed by means of the Spearman correlation. 
A P value <0.05 was deemed to indicate significance. 
 
  
Results 
 
Procedure effects 
Procedures were stopped when all portions of the nodule had been ablated, with 
particular attention being paid to danger triangle and the nodular capsule. Procedures 
lasted 7 ± 3 minutes on average (range: 2:45 – 15:00 min), with a mean delivery of 
1575 ± 767 J/ml (range: 13607 – 43459 J; 349 – 3171 J/ml) at a mean power of 42 ± 5 
W (range: 40 - 50 W). On enrolment, the mean volume of the nodules was 22 ± 14 ml 
(range: 7 - 38 ml) and the total gland volume was 39 ± 16 ml (range: 14 - 76 ml) (table 
3). Table 3 reports the reduction in nodular and thyroid volumes at each time-point of 
the study. The percentage volumetric reductions in the RFA-treated thyroid nodules 
and in the thyroid volume were statistically significant at 1, 3, 6, 12 and 24 months 
(table 3).  
There was no significant correlation between percentage volume reduction and joules 
administered during the procedure, baseline nodule volume or years since diagnosis. A 
significant correlation between better reduction and patient age (P = 0.039; r = 0.365; 
CI 95% = 0.008-0.639) was found (figure 1). 
 
Changes in thyroid parameters  
Parameters of thyroid function at the baseline and at the various time-points are 
reported in table 4. One week after thyroid RFA, F-T4 levels were significantly (P=0.02) 
increased, although in the normal range. By the month-1 follow-up examination, they 
had returned to baseline levels (table 3). In one case (3%) f-T4 increased beyond the 
  
normal range, probably owing to iatrogenic destructive thyrotoxicosis, but 
spontaneously returned to the normal range about 1 month after thyroid RFA. During 
follow-up, one patient developed overt hypothyroidism, which required L-T4 
replacement therapy; this patient had previously displayed TSH and f-T4 values 
suspicious for overt hypothyroidism. F-T3 and TSH levels did not exhibit significant 
changes (table 4). None of the subjects on L-T4 therapy on enrolment had to increase 
the dosage. Thyroid autoantibody positivity was observed in 28% of patients (n= 9); 
this percentage was the same at the last evaluation. Thyroglobulin levels were 
significantly increased 1 week after thyroid RFA (P = 0.049) and returned to values 
comparable to the baseline approximately one month after thyroid RFA (P = 0.77) 
(table 4). No significant correlation was found between percentage volume reduction 
and hormonal data (TSH, f-T3, f-T4, thyroglobulin on enrolment and after procedure). 
 
Subjective complaints  
During the procedure, 28 patients (88%) experienced discomfort in the neck, 12 
patients (38%) experienced pain which required a reduction in the voltage of the 
source of radiofrequency, 4 (13%) suffered slight haemorrhage from the site of 
electrode insertion and 1 patient (3%) had neck oedema. Twelve patients (38%) did not 
experience any problems. 
One week after the procedure, 12 patients (38%) did not have any problems, 9 (28%) 
felt discomfort in the neck, 3 (9%) felt pain (mean VAS score: 2), 3 (9%) had a 
haematoma, and 1 (3%) had oedema in the neck. These symptoms did not require any 
  
kind of medication and resolved spontaneously during the 1st month. No patient 
suffered hoarseness, dysphagia, nodule rupture, major bleeding or infections. 
The VAS score was 3±3 at the baseline; at the last evaluation, it  was lower, but not 
significantly so (p = 0.06) (table 5). Specifically, it decreased significantly from the 1st 
month to the 6th month after thyroid RFA, but then seemed to worsen at 12, 24 and 36 
months (table 5). 
In patients with VAS >0 on recruitment (n=23), 74% (n=17) reported an improvement 
in symptoms, 17% (n=3) stability of symptoms and 17% (n=3) worsening of neck 
symptoms. 
The score on each single scale of the ThyPRO questionnaire was unchanged after 
thyroid RFA (figure 2). By contrast, the “general scale” of ThyPRO showed a significant 
improvement in scores (P=0.02) from the baseline to the 3rd month; this QoL 
improvement persisted over time (figure 3). Likewise, analysis of the ThyPRO scores of 
group 1 patients (nodule reduction>30%) revealed that single scores on the 13 scales 
did not change significantly.  
  
Discussion 
We performed all thyroid RFA procedures according to the consensus statement of the 
Korean Society of Thyroid Radiology [3]. The duration of thyroid RFA in our hands was 
much lower than that reported in the literature [8]. This difference can be ascribed to 
the personal choice of the operator, whose main objective was to prevent severe side 
effects. Indeed, the appearance of transient hyperechoic zone during thyroid RFA may 
hinder visualization of the electrode, thus jeopardizing the safety of the procedure. It is 
therefore not surprising that the mean reduction in nodular volume was slightly lower 
in our hands than in other centres [4]. However, the reduction in volume remained 
stable over time, at least up to the 24th month after the procedure, as reported in 
other studies [4, 9].  
To our knowledge, there are no data on the relationship between thyroid RFA efficacy 
and nodule echogenicity or the presence of UNG or MNG; this issue was addressed in 
our study, but no significant results emerged. Similarly, no study in the literature has 
analysed the response to thyroid RFA as a factor of patient age, sex, BMI, time since 
diagnosis, L-T4 therapy and hormonal status; our evaluation did not yield a significant 
correlation between thyroid RFA efficacy and any of these features, apart from age. 
Indeed, in our cohort, older patients displayed a better reduction in thyroid nodule 
volume; we do not know the reason for this finding, but we might hypothesize a 
different intracellular content in older patients, which could facilitate necrosis after 
thyroid RFA. 
In two of our patients, thyroid RFA was performed approximately one year after 
percutaneous ethanol ablation. In these two patients, there was no significant 
  
reduction in volume even after thyroid RFA; in a study by Sung et al. (2013), both 
thyroid RFA and percutaneous ethanol ablation of cystic thyroid nodules seemed to be 
effective, achieving similar volume reductions[10].  
Thyroid RFA-treated patients did not have any serious complications during or after 
the procedure; no patient reported symptoms or showed signs of complications of 
severity comparable to those cited in the literature, which reports a percentage of 
around 3-5% [11]. 
In our study, thyroid RFA did not lead to significant changes in thyroid function or 
thyroid autoimmunity. The levels of thyroglobulin and f-T4 increased significantly a 
week after the procedure, but returned to their previous values about one month after 
the treatment. These data have not been reported in any other study.  
Many studies have reported improvements in neck discomfort and aesthetic 
symptoms after thyroid RFA. In the literature, aesthetic issues have been assessed by 
means of a score (generally from 1 to 4 or from 0 to 3) [12]. In our study, we used the 
aesthetic scale of ThyPRO, which did not reveal any improvement after thyroid RFA. 
However, it should be noted that all our patients had very low baseline scores on this 
scale. In many studies, neck discomfort has been evaluated by means of a score 
(usually from 1 to 4 or from 0 to 3) [3]. Like us, Baek et al. [9] used a 10 cm VAS 
analogue scale [9]. A recent study by Valcavi et al. (2015) reported an improvement in 
VAS from 5.6 ± 3.1 cm to 1.9 ± 1.3 cm [14] after 2-year follow-up of benign thyroid 
nodules treated with thyroid RFA. 
Our patients displayed a significant improvement in VAS at the 1st, 3rd and 6th month 
follow-up examinations; however, the significance seemed to shrink with time. Thus, 
  
at 12 months, the improvement in neck discomfort was at the limit of significance; this 
borderline significance was lost after the 12th month, probably because of the 
decrease in the number of patients at the subsequent time-points of the study. 
QoL is defined as a person’s perception of his/her position in life, in the context of the 
culture and system of values in which he/she lives and in relation to its objectives, 
expectations, standards and concerns [14]. 
In the case of thyroid diseases, QoL is often assessed by means of various inventories 
(e.g. SF-36, Hamilton scale and the Kellner Symptoms Questionnaire). Questionnaires 
for QoL evaluation have been used in numerous benign and malignant thyroid 
diseases, such as benign goitre treated with RAI following rhTSH premedication, 
autoimmune hypothyroidism and chronic autoimmune thyroiditis [14-23]. Only one 
study has reported changes in QoL in patients treated with RFA for benign thyroid 
nodules;  Valcavi et al. (2015) reported a significant improvement in QoL in 40 patients 
treated with RFA for benign thyroid nodules, as assessed by means of the Physical 
Component Summary (from 50.4 ± 8.9 to 54.5 ± 5.3) and Mental Component Summary 
(from 36.0 ± 13.3 to 50.3 ± 6.3) after 2 years of follow-up [13]. This questionnaire 
consists of 8 scales, 3 of which concern physical health (physical functioning, limitation 
of specific activities due to physical problems, pain), 2 reflect  general health (general 
health and vitality), and the remaining 3 measure aspects of psychological and 
emotional health (social activities, limitation of specific activity due to emotional 
problems, mental health). The Physical Component Summary and Mental Component 
Summary are two synthetic indexes that summarize the results of the 8 scores in just 
two numbers: the higher the score, the better the level of health perceived [13]. 
  
In our study, none of the scores on the single ThyPRO scales changed significantly from 
the baseline to the last evaluation. However, the overall score was significantly lower 
at the month-3 evaluation, and this reduction persisted over time. To our knowledge, 
no data on QoL evaluated by means of ThyPRO in patients treated with RFA for thyroid 
nodules have been reported.  
Some studies in the literature have evaluated QoL by means of ThyPRO after other 
therapies for goitre. Fast et al. (2014) found that the majority of patients treated with 
rhTSH for goitre reported an improvement in symptoms on the specific ThyPRO scale 
concerning goitre, and that the improvement persisted at least up to the 36th month 
[19]. Moreover, according to studies conducted by two groups of surgeons on patients 
who had undergone thyroidectomy for goitre, QoL improved significantly after surgery, 
whether total thyroidectomy or hemithyroidectomy had been performed [24, 25]. 
  
Conclusions 
In conclusion, our study shows that thyroid RFA can be effective both in reducing the 
volume of the nodule and in alleviating neck symptoms. In our study, the efficacy of 
thyroid RFA correlated with patient age. The procedure proved to be safe; adverse 
events were few and mild in comparison with surgery or radioiodine therapy. Thyroid 
RFA was well tolerated by patients and VAS scores improved a few months after the 
procedure. However, in our cohort of patients, scores on the 13 individual ThyPRO 
scales did not improve after RFA for benign non-functioning thyroid nodules.  By 
contrast, the “general scale” of ThyPRO, which answers the question “In the last 4 
weeks, has thyroid disease  had a negative effect on your quality of his life?”, showed a 
significant improvement in scores, and this QoL improvement persisted over 
time.Further studies will be necessary in order to confirm or contradict our data, 
especially in a cohort of patients with a better response to thyroid RFA in terms of 
nodule volume reduction.  
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Table 1: data on group 1 and 2 patients.  
(NS= not significant; MNG: multinodular goitre; UNG: uninodular goitre) 
 
 Group 1 Group 2 P 
Males / Females 03 / 13 05 / 11 0.6 
Age (years; mean ± SD) 60 ± 12 52 ± 14 0.71 
BMI (kg/m2; mean ± SD) 25 ± 3 27 ± 5 0.95 
Time since diagnosis (years; mean ± SD) 13 ± 13 7 ± 8 0.64 
VAS score (mean ± SD) 3 ± 3 3 ± 3 1 
MNG / UNG 12 / 04 10 / 06 0.74 
Location (right / left) 09 / 07 10 / 06 0.87 
TSH (mIU/L; mean ± SD) 1.55 ± 1.13 1.24 ± 0.85 0.63 
Nodule volume at baseline (ml; mean ± SD) 19 ± 10 26 ± 16 0.89 
Joules administered (J/ml; mean ± SD) 1819 ± 712  1346 ± 767 0.72 
Follow-up (months; mean ± SD) 15 ± 11 14 ± 9 0.85 
Volume reduction (%) 45 ± 9 11 ± 17  P<0,0001 
 
 
  
Table 2: ThyPRO scores at baseline in groups 1, in group 2 and total patients (mean ± 
SD).   
Significant P scores are in italic form.  
 
 Total patients Group 1 Group 2 
 Baseline Last 
Evaluation 
P Baseline Last 
Evaluation 
P Baseline Last 
Evaluatio
n 
P 
Goiter 
symptoms 
16 ± 15 18 ± 13 0,8
7 
16 ± 16 18 ± 2 0,71 17 ± 15  14 ± 12  0,6 
Hyperthyroidis
m symptoms 
13 ± 13 10 ± 9 0,7
4 
11 ± 13 10 ± 7 0,87 14 ± 13 11  ± 14 0,94 
Hypothyroidis
m symptoms 
15 ± 14 19 ± 10 0,7
1 
15 ± 13 19 ± 0 0,68 16 ± 15  17  ± 19 0,85 
Eye symptoms 7 ± 8 19 ± 22 0,0
9 
8 ± 9 19 ± 16 0,19 7 ± 7 6  ± 7 0,88 
Tiredness 33 ± 17 25 ± 10 0,5
3 
28 ± 17 25 ± 7 0,69 34 ± 17 32  ± 14 0,6 
Cognitive 
problems 
12 ± 18 13 ± 12 0,9
6 
15 ± 22 13 ± 9 0,9 9 ± 8 8  ± 9 0,84 
Anxiety 19 ± 18 25 ± 35 0,6
6 
13 ± 12 25 ± 25 0,19 24 ± 21 20  ± 16 0,64 
Depressivity 26 ± 18 24 ± 8 0,9
5 
23 ± 17 24 ± 6 0,97 28 ± 18 20  ± 18 0,37 
Emotional 
susceptibility 
22 ± 17 24 ± 18 0,9 20 ± 17 24 ± 13 0,79 27 ± 17 19  ± 16 0,5 
Impaired social 
life 
8 ± 13 16 ± 22 0,4
4 
5 ± 9 16 ± 16 0,2 11 ± 15 5  ± 8 0,45 
Impairmed 
daily life 
9 ± 13 17 ± 23 0,4
4 
8 ± 12 17 ± 17 0,41 10 ± 14 7  ± 11 0,63 
Impaired 
sexlife 
9 ± 20 32 ± 26 0,1
4 
7 ± 21 32 ± 19 0,15 12 ± 19 8  ± 11 0,66 
Cosmetic 
complaints 
10 ± 13 11 ± 15 0,9
5 
8 ± 13 11 ± 11 0,78 12 ± 13 4  ± 7 0,19 
General score 29 ± 7 0 ± 0 0 26 ± 27 0 ± 0 0,02 25 ± 26 13  ± 21 0,07 
Mean values 16 ± 2 19 ± 6 0,7
2 
14 ± 11 19 ± 11 0,7 17 ± 12 13  ± 11 0,44 
 
  
Table 3: reduction (mean ± SD in ml and %) of nodule and thyroid with significances. 
(N= number of patients;  *1= P=0.55; *2= P=0.16; *3= P=0.0017; *4= P=0.0012; *5= 
P=0.0006; *6= P<0.0001) 
 
 N Nodule 
volume 
(ml) 
Nodule 
volume  
(%) 
Thyroid 
volume  
(ml) 
Thyroid 
volume  
(%) 
Baseline 32 22 ± 14 - 39 ± 16 - 
1st month 32 18 ± 11 - 18 ± 18 *6 34 ± 15 - 10 ± 18 *3 
3rd month 30 16 ± 10 - 27 ± 21 *6 31 ± 15 - 16 ± 21 *6 
6th month 26 16 ± 11 - 30 ± 24 *6 33 ± 18 - 13 ± 21 *5 
12th month 22 16 ± 10 - 27 ± 22 *6 31 ± 15 - 14 ± 24 *4 
24th month 10 17 ± 11 - 26 ± 24*1 31 ± 14 - 17 ± 19 *6 
36th month 2 12 ± 6 - 45 ± 5 *6 40 ± 25 - 5 ± 30 *2 
 
 
  
Table 4: changes in thyroid function.  
(N= number of patients; *1=P=0.03; *2= P=0.04 ) 
 
 N TSH (mIU/L) f-T3 (pmol/L) f-T4 (pmol/L) Thyroglobulin (µg/L) 
Baseline 32 1.4 ± 0.99 4.88 ± 0.65 15.4 ± 2.29 399.15 ± 778.28 
1st week 32 1.36 ± 1.22 4.88 ± 0.52 17.13 ± 3.56 *1 1243.70 ± 2254.49 *2 
1st month 32 1.27 ± 0.76 4.82 ± 0.60 14.80 ± 3.41 343.82 ± 779.13 
3rd month 30 1.26 ± 0.86 4.96 ± 0.60 15.70 ± 2.33 325.06 ± 686.08 
6th month 26 1.34 ± 0.75 4.73 ± 0.49 14.54 ± 3.27 494.48 ± 1114.1 
12th month 22 1.33 ± 0.92 4.72 ± 0.66 15.02 ± 1.21 280.55 ± 523 
24th month 10 1.35 ± 0.94 4.98 ± 0.55 14.67 ± 2.39 297.17 ± 759.51 
36th month 2 1.08 ± 0.5 6.03 ± 0.28 14.48 ± 0.09 67 ± 91.2 
 
  
Table 5: changes in VAS score (mean ± SD).  
(N= number of patients; *= P=0.02 ) 
 
 N score 
Baseline  32 3 ± 3 
1st week 32 2 ± 2 
1st month 32 1 ± 2 * 
3rd month 30 1 ± 2 * 
6th month 26 1 ± 2 * 
12th month 22 1 ± 2 
24th month 10 3 ± 2 
36th month 2 3 ± 4 
 
 
 
 
  
Figure 1: correlation between nodule reduction (%) and age of patients.  
The x-axis indicates the age of the patients; the y-axis indicates the volume reduction 
of thyroid nodules. In our study, there was a significant correlation between 
percentage nodule reduction and patient age: older patients had a greater reduction. 
 
 
 
  
Figure 2: changes in ThyPRO score. 
The six graphs show the scores on the 13 scales of ThyPRO at different times of the 
study (1 month, 3 months, 6 months, 12 months, 24 months and 36 months) 
compared with the baseline. None of the 13 scales  significantly changed from the 
baseline at any time of the study. 
 
 
 
 
  
Figure 3: “general score” of ThyPRO.  
The “general score” of ThyPRO, which answers the question “In the last 4 weeks, has 
thyroid disease  had a negative effect on your quality of life?”, improved from the 3rd 
month onwards. * = P <0.05 
 
 
 
 
  
CHAPTER 3:  
Quality of life in patients treated with percutaneous laser ablation for non-
functioning benign thyroid nodules: a prospective single-center study.  
Oddo S, Felix E, Mussap M, Giusti M.  
Korean Journal of Radiology. 2018; 19: 175-184. 
 
Background 
 
Since 2010, the American Association of Clinical Endocrinologists-Associazione Medici 
Endocrinologi-European Thyroid Association (AACE-AME-ETA) guidelines have 
recommended laser ablation (LA) as a possible therapeutic option for the treatment of 
benign symptomatic thyroid nodules in patients who refuse thyroidectomy, or in those 
with comorbidities that contraindicate surgery [1]. LA tends to be less expensive than 
thyroidectomy, whether total or partial. LA also does not require hospitalization, and 
causes only mild and rare adverse events. Thus, it can be undertaken in patients with 
contraindications for surgery or in those who refuse surgery. Moreover, compared 
with surgery, minimally invasive procedures for benign thyroid nodules preserve 
normal thyroid function [2]. 
Other non-surgical treatments for benign thyroid nodules include other percutaneous 
techniques, such as ethanol ablation, microwave or radiofrequency, and high-intensity 
focused ultrasound [3]. LA, radiofrequency ablation (RFA), and ethanol ablation are 
also utilized for recurrent thyroid cancer [3].  
  
Other non-invasive techniques for reducing benign thyroid nodules are radioiodine 
with recombinant thyroid-stimulating hormone (TSH) [4] or suppressive levothyroxine 
(L-T4) therapy [5].  
While many studies have reported reductions in treated nodules and improvements in 
the sense of pressure and in esthetic symptoms [3] after LA, none have described 
changes in quality of life (QoL). The aim of our study was to therefore evaluate QoL 
changes in a cohort of patients treated with a single session of LA for benign thyroid 
nodules. 
  
Materials and methods 
 
We conducted this prospective single-center study at the endocrinology department of 
IRCSS AOU San Martino University-IST of Genoa (Italy) from September 2014 to 
September 2015. All patients signed an informed consent form that included a detailed 
explanation of the LA procedure and its purpose. Our Ethics Committee approved the 
LA treatment protocol. 
 
Subjects 
We evaluated patients with benign thyroid nodules, solid or nearly completely solid 
(with a liquid component not exceeding 30%), single or clearly detectable in a 
multinodular goiter, with a view to undergoing percutaneous LA [3]. These patients 
had either refused total or subtotal thyroidectomy, or had comorbidities that 
contraindicated surgery.  
We enrolled 14 patients (12 females and 2 males) aged between 38 and 72 years 
(mean ± standard deviation [SD], 55 ± 10 years) with a single thyroid nodule (n = 8, 
57%) or a predominant thyroid nodule in a goiter (n = 6, 43%). 
These nodules, which had been discovered 7 ± 8 years earlier, were located in the right 
lobe in 10 patients (71%) and in the left lobe in six patients (29%). No patient had 
undergone ethanol ablation of the nodule or radioiodine therapy. Two patients were 
on L-T4 replacement therapy for hypothyroidism at a mean dosage of 616 ± 124 
μg/weekly. Table 1 reports on patients’ features. 
 
  
Pre-ablation assessment and procedures 
Before performing LA, we excluded contraindications for the procedures, as 
recommended in the Consensus Statement of the Korean Society of Thyroid Radiology 
for RFA [6]. Before LA, patients underwent the following: a review of clinical data and 
physical examination; routine blood tests and thyroid function tests (free T3 [f-T3], 
free T4 [f- T4]; TSH); evaluation of anti-thyroid peroxidase antibodies (TPOAbs), 
calcitonin, thyroglobulin, electrocardiography; and a phoniatric examination. We 
evaluated the volume (mL) of the nodule undergoing LA by means of the ellipsoid 
formula: antero-posterior diameter x latero-lateral diameter x cranio-caudal diameter 
in millimeter (mm) x 0.52 / 1000. We also used this formula to calculate the total 
volume of each thyroid lobe [7].  
Before LA, patients underwent fine needle aspiration of the nodule on two separate 
occasions, to confirm benignity cytologically (Thy 2 in accordance with the British 
Thyroid Association [8]). Only patients with a finding of benignity on both occasions 
underwent LA.  
Patients filled out both a symptomatic visual analogic scale (VAS) that rated discomfort 
in the neck and a 13-scale Thyroid-specific Patient Reported Outcome (ThyPRO) QoL 
questionnaire validated for patients with thyroid disease [9].  
Clinical examinations, assessments of thyroid function and thyroid autoimmunity, and 
VAS scores were repeated after one week and 1, 3, 6, and 12 months. ThyPRO and 
ultrasound thyroid volume were evaluated after 1, 3, 6, and 12 months. We performed 
follow-up ultrasound examinations using a MyLab Five (Esaote®, Genoa, Italy) 
ultrasound scanner with a 7.5 MHz linear transducer (LA 523, Esaote®). We repeated 
  
phoniatric examination if symptoms related to chordal dysmotility appeared after the 
procedure. 
 
Procedures and Methods 
Laser ablation was performed in an out-patient regimen. Antiplatelet and 
anticoagulant therapies were suspended a week before the procedure. On the day of 
the procedure, patients were in a state of 8-hour fasting. After placement of a venous 
catheter, patients underwent intravenous infusion for over 30 minutes of ketorolac 20 
mg (Tora-dol®, Recordati Spa, 10 mg/mL, Milan, Italy) and ranitidine 50 mg 
(Ranitidina®, 50 mg/5mL, S.A.L.F. Spa, Cenate Sotto, Italy) diluted in 100 mL of 0.9% 
saline solution. Subsequently, intravenous ketorolac 40 mg (Tora-dol® Recordati Spa, 
10 mg/mL) and ranitidine 50 mg (Ranitidina® 50 mg/5 mL, S.A.L.F Spa) were 
administered in 500 mL of 0.9% saline for about five hours (during and after LA). In 
subjects allergic to ketorolac or in patients with moderate-to-severe renal impairment, 
premedication with intravenous paracetamol (500 mg) (Perfalgan®, 10 mg/mL, 50 mL, 
Bristol-Myers Squibb Srl, Roma, Italy) was carried out before and during the procedure. 
We placed patients on an operating table in the supine position with the neck 
hyperextended. Before LA, we performed a careful US examination to evaluate neck 
anatomy and ensure preservation of the “danger triangle” during procedures (10). 
Local anesthesia with 2% lidocaine (Lidocaina Cloridrato®, 20 mg/mL, Monico Spa, 
Mestre, Italy) was carried out at the puncture site. If the patient did not tolerate pain 
during ablation, we reduced the power or turned it off for several seconds.  
  
In three patients, we performed percutaneous drainage of cystic intranodular fluid 
before the procedure. LA was performed in a single session by a single operator. The 
operator had one year of experience with LA, four years of experience of thyroid RFA, 
and 22 years of experience with fine-needle aspiration biopsy, by means of 300 μm 
diameter fibers and a 21-Gauge Chiba-needle (ELESTA®, Calenzano, Italy). Procedures 
were performed by means of a commercially available US scanner (Echo-laser X4®, 
Esaote®) equipped with a 7.5 MHz linear transducer (LA 332, Esaote®) with a 1064 μm 
diode laser unit with a maximum of four laser sources, each with an individual energy 
emission setting and independent activation.  
The operator was positioned at the patient’s side and inserted from one to two fibers 
into the longitudinal length of the nodule, forming a shape matching the ellipsoid of 
thyroid nodule. The initial energy was delivered at 1200–1800 Joules per fiber with an 
output power of 2−4 W, starting at one centimeter from the bottom of the lesion. One 
or two 1-cm pull-backs were programmed to maximize the ablation volume in a single 
LA session. The number of fibers, their placement, the number of pull-backs and total 
energy delivered were tailored to the shape and volume of each thyroid nodule, as 
described by Baek et al. (11). LA lasted 16 ± 2 minutes on average (range: 13−19 
minutes), with a mean delivery of 4459 ± 1525 J (range: 1713−6203 J), one or two 
fibers (mean 1.7) and one or two pull-backs (mean 1.3). The energy load in J/mL was 
340 ± 196 (range: 87−742 J/mL). Light irradiation was continuous, but was suspended 
in the event of pain or in order to reposition the fibers.  
After LA, patients received a compressive bandage and ice to apply to the neck. 
Patients were allowed a light meal before being discharged in the early afternoon. All 
  
subjects received a domiciliary prescription for steroid administration (prednisone 25 
mg for three days, 12.5 mg for three days, 6.25 mg for three days) and gastric 
protection, if not already ongoing. 
 
Laboratory tests 
We measured TSH, f-T3, and f-T4 by ultra-sensitive chemiluminescence immunoassay 
(Cobas® e602, Roche Diagnostics, Milan, Italy). The normal ranges are: 0.27−4.2 mIU/L 
for TSH, and 2.76−7.07 pmol/L and 11.97−21.88 pmol/L for f-T3 and f-T4. We 
evaluated TPOAbs by means of DiaSorin (Saluggia, Italy); we regarded concentrations < 
100 mU/L as negative. We measured calcitonin by chemiluminescence immunoassay 
(DiaSorin); in our laboratory, the normal value is < 10 ng/L. We performed automated 
complete blood counts using an ADVIA 2120 automated counter (Siemens Healthcare, 
Milan, Italy); coagulation tests on an automated BCS analyzer (Siemens Healthcare); 
and biochemical tests for the routine assessment of hepatic and renal function on the 
fully-automated Cobas® c701 platform (Roche Diagnostics). 
 
Questionnaires 
We evaluated the subjective benefits of LA several times during the study through a 
VAS with a score ranging from 0 (no symptoms/discomfort) to 10 (highest level of 
symptoms/discomfort). We assessed QoL before the procedure (baseline), and after 1, 
3, 6, and 12 months, by means of ThyPRO, a validated questionnaire for thyroid 
diseases (9), which consists of 13 scales with multiple-choice answers (0 = “none”; 1 = 
“slight”; 2 = “moderate”; 3 = “severe”; 4 = “very severe”). The ThyPRO scales concern 
  
the following aspects: goiter symptoms, hyperthyroid symptoms, hypothyroid 
symptoms, eye symptoms, tiredness, cognitive problems, anxiety, depression, 
emotional susceptibility, impaired social life, impaired daily life, impaired sex life, and 
cosmetic complaints.  
We also evaluated a further scale, dubbed “general score”. It assesses answers to the 
question, “In the last 4 weeks, has thyroid disease had a negative effect on your QoL?” 
Lastly, we considered the mean values of the 13-scale score [9]. 
 
Statistical analysis 
All data were analysed by means of GraphPad Prism for Windows (Version 6.0, 
GraphPad Software, San Diego, CA, USA). The data are presented as means ± SD, 
unless otherwise indicated. Continuous data were compared by means of the Mann-
Whitney test, while percentages were compared by means of the Fisher test. 
Correlations between variables were assessed by means of the Spearman correlation. 
A P value <0.05 was deemed to indicate significance. 
 
  
Results 
 
Procedure effects 
On enrolment, the mean volume of the nodules was 19 ± 14 mL (range: 5−55 mL) and 
the total gland volume was 32 ± 16 mL (range: 13−59 mL). Table 2 reports the mean 
volume of nodules and thyroid at each time-point of the study. Figure 1 reports on the 
mean volumetric changes at different time-points.  
After LA, we found a progressive reduction in nodule volume: -37 ± 23%, -55 ± 22%, -
53 ± 25%, -58 ± 25% at the first, third, sixth and twelfth month, respectively (p < 0.01 
vs. baseline at the first, third, and sixth month, and p < 0.05 at the twelfth month). The 
percentage reductions in thyroid volume were significant at 3, 6, and 12 months (p < 
0.01, < 0.05, < 0.05, respectively) (Fig. 1). At the 12-month follow-up, we observed a 
reduction of > 50% in 86% of the patients treated (p < 0.01). In two patients (14%), 
however, LA resulted in a nodule volume reduction of < 20%.  
Figure 2 shows a nodule at the baseline of the study (Fig. 2A) and the same nodule 12 
months after LA (Fig. 2B). 
 
Changes in thyroid parameters  
Table 3 depicts the parameters of thyroid function at the baseline and at the various 
time-points. f-T4, f-T3, thyroglobulin, and TSH levels did not exhibit significant changes 
(Table 3). None of the patients developed hypothyroidism. None of the subjects on L-
T4 therapy on enrolment had to increase the dosage. TPOAbs were positive in 21% of 
patients (n = 3); this percentage was the same at the last evaluation. 
  
 
Subjective complaints  
During the procedure, four patients (26%) experienced discomfort in the neck, and 
three patients (21%) experienced pain. Seven patients (50%) did not experience any 
problems. One week after the procedure, five patients (36%) did not have any 
problems, four (26%) felt discomfort in the neck, three (21%) felt pain (mean VAS score 
was 3 ± 2), three (21%) had edema in the neck and one (7%) had a hematoma. These 
symptoms did not require any kind of medication and resolved spontaneously during 
the first month. No patient developed hoarseness, dysphagia, nodule rupture, major 
bleeding or infections.  
The VAS score at the baseline was 5 ± 3, and was significantly lower at each 
subsequent evaluation: from the first week after LA until the last evaluation at the 
twelfth month (Fig. 3). The VAS score improved in 100% of patients.  
Table 4 shows the mean score on each ThyPRO scale at each time-point of the study. 
The data shows a significant improvement on the scale of “goiter symptoms” from the 
first month onwards, and on the scale of “general score” from the sixth month 
onwards. The mean values of the 13 scales also improved significantly from the sixth 
month onwards (Fig. 4). These improvements persisted over time. By contrast, no 
significant changes in the other scales were recorded. 
  
Discussion 
The present paper reports our preliminary data on the use of a single session of LA to 
treat 14 benign thyroid nodules in 14 patients recruited over 12 months and followed 
up for 12 months.  
We used standard procedures recommended by the Korean RFA Guidelines [7, 11], 
and we performed LA after excluding contraindications.  
The mean reduction in the volume of our nodules appears to be similar or slightly 
lower than those observed in other centers: 58 ± 25%. At 12 months, the mean nodule 
volume reduction was -72 ± 11% in a study by Pacella et al. [12], -84 ± 13% in a study 
by Achille et al. [13], -59 ± 22% in a study by Papini et al. [14], - 51 ± 11% in a study by 
Døssing et al. [15], and -70 ± 16% in a study by Mauri et al. [16].  
The mean reduction in the volume of our nodules appears to be similar or slightly 
lower than that observed after a single session of RFA: -74 ± 12% in a study by Mauri et 
al. [16], -69 ± 14% in a study by Cesareo et al. [17], and 77 ± 3% in a study by Faggiano 
et al. [18], -79.7% in a study of Baek et al. [19], -84 ± 15% in a study of Jeong et al. [20]. 
We achieved more than 50% volume reduction at the 12 months in 86% of nodules. 
This result is comparable to, or better than, the data presented in a three-year 
multicenter prospective study (67.3%) [14].  
Laser ablation can lead to normalization of TSH in patients with hyperthyroidism with 
“hot” nodules [21]. The literature reports a change in thyroid function (hypo-or 
hyperthyroidism) in 2% of patients after LA [12]. By comparison, in our study that 
enrolled only euthyroid patients, LA did not lead to significant changes in thyroid 
function and preserved euthyroidism. This data confirms the safety of this procedure 
  
and may prompt percutaneous techniques to be preferred to surgery, which causes 
hypothyroidism in 100% of cases after total thyroidectomy and in 22% of cases after 
hemithyroidectomy [2]. In comparison studies between RFA and surgery, there were 
also no hypothyroidism patients after RFA [22, 23].  
Most of our patients did not experience any problems either during or after LA. In our 
study, adverse events were few and mild; indeed, the main complaints were 
“discomfort in the neck” and “pain” during and after LA. If these symptoms started 
after LA, they resolved spontaneously in a few weeks; if they arose during LA, they 
were alleviated by reducing the energy delivered or turning off the fibers for several 
seconds. In any case, pain was mild, with the mean VAS score being 3.  
Other adverse events in our experience were asymptomatic edema of the neck in one 
patient and a superficial hematoma in another patient; however, these resolved 
spontaneously. Our patients did not suffer other major adverse events, such as 
dysphagia, nodule rupture, pericapsular bleeding, vagal symptoms with bradycardia, or 
infections, which were reported in 0.5% of cases in a study by Pacella et al. [12] on 
1280 nodules treated with LA. In that study, the rate of major complications was lower 
in patients treated without local anesthesia or with no conscious sedation than in 
patients managed with local anesthesia and conscious sedation. Conversely, 
complaints of side effects were more frequent in subjects treated without local 
anesthesia [12]. In our protocol, we did not use conscious sedation, which probably 
explains why we observed no major complications and few adverse events. In our 
cohort of patients, we did not administer local sub-capsular anesthesia, but 
subcutaneous tissue anesthesia. Furthermore, we infused analgesic and anti-
  
inflammatory drugs before and during the procedures and prescribed steroids for 
some days after discharge, in order to minimize complications. While these 
precautions probably helped to minimize complications, they did not completely 
alleviate pain and discomfort in the neck.  
It should be borne in mind that proximity of the light to the capsule cause pain and 
discomfort in the neck. If patients complain of these symptoms during the procedure, 
the patients can thereby help the operator not to exceed the capsule of the treated 
nodule and minimize adverse events [12]. In any case, the complications of LA, and of 
other minimally invasive procedures, such as RFAs [11], are fewer and milder than 
those of thyrodectomy, whether total or partial. The types and frequencies of adverse 
events of thyroid surgery are described in a recent review by a group of Indian 
surgeons (24). A study by Wang et al. [25] describes the prevalence of complications 
after conventional and endoscopic thyroidectomies as follows: transient laryngeal 
nerve palsy in 5.4%, transient hypocalcemia in 3.6%, bleeding in 0.5% and hematoma 
in 0.5% of cases. Furthermore, discomfort in the neck and chest was reported in 80% 
of patients on the third day, and pain in the neck and chest in 10% of patients one 
month after thyroidectomy [25]. 
Many studies have reported improvements in neck discomfort and esthetic symptoms 
after LA. In a study by Valcavi et al. [21], neck symptoms improved in 73% of patients, 
were unchanged in 23%, and worsened in only 4%; esthetic symptoms improved in 
71% of patients, were unchanged in 24%, and worsened in 5%. Moreover, in a study by 
Pacella et al. [12], neck symptoms improved in 10−49% of cases, and esthetic 
symptoms improved in 8−86% of cases. In addition, in a study by Achille et al. [13], 
  
esthetic problems were completely resolved in 87% of treated patients, reduced in 9%, 
and unchanged in 2%, and pressure symptoms were resolved in 88% of cases. In our 
study, esthetic complaints were assessed by means of the cosmetic scale of ThyPRO, 
which revealed no improvement after LA. However, it should be noted that the 
baseline scores on this scale were very low in all our patients.  
Quality of life is defined as a person’s perception of his/ her position in life, in the 
context of the culture and system of values in which he or she lives and in relation to 
his or her objectives, expectations, standards, and concerns [26]. In thyroid diseases, 
besides ThyPRO, QoL is often calculated by means of various questionnaires: the Short 
Form-36 [27], the SF-12 Health Survey [28], the Hamilton Depressive Scale [29], and 
the Kellner Symptoms Questionnaire [9, 30].  
While the Hamilton Depressive Scale (24-scale multiple-choice questionnaire) and 
the Kellner Symptoms Questionnaire (92-item questionnaire with Yes/No answers) 
focus more on the psychological aspects of QoL, the Short Form-36 (11-scale multiple-
choice questionnaire), the slimmer SF-12 Heath Survey (12-item multiple-choice 
questionnaire), and ThyPRO analyze both physical and mental health [9, 27-30]. We 
chose to utilize ThyPRO because it has been validated for thyroid diseases and could 
therefore provide a more detailed analysis of QoL in patients undergoing thyroid LA. 
Indeed, the 13 scales of ThyPRO investigate several aspects of life that may be 
impaired by goiter-related compression symptoms or discomfort in the neck, by 
esthetic alterations and by an altered thyroid function (both hypo- and hyper-
thyroidism). As of this writing, no literature has reported on changes in QoL in patients 
treated with LA. However, ThyPRO has been used to assess QoL in numerous benign 
  
and malignant thyroid diseases. Regarding the use of questionnaires to evaluate 
changes in QoL in patients treated with thermal ablation for thyroid nodules, a study 
by Valcavi et al. [31] reported a significant improvement in QoL. The study assessed 
QoL using the Physical Component Summary and Mental Component Summary of 
Short Form-12 after two years of follow-up and in 40 patients treated with RFA for 
benign thyroid nodules. In the that study, both the Physical Component Summary and 
the Mental Component Summary significantly improved after one year, and remained 
stable from year one to year two.  
Our group recently published a study on changes in QoL, as assessed by means of 
ThyPRO after RFA of benign thyroid nodules. In that study, we did not find a significant 
improvement in ThyPRO scales, except for the “general score,” which improved after 
three months [32]. The cause of less improvement of ThyPRO scales in this study [32] 
was probably induced by low volume reduction: the majority of patients showed less 
than a 50% volume reduction. Moreover, four patients showed increased nodule 
volume after RFA. The mean volume reductions of nodule was -18 ± 18%, -30 ± 24% 
and -27 ± 22% after RFA vs. -37 ± 23%, -53 ± 25% and -58 ± 25% in LA at 1, 6, and 12 
months, respectively, although the features of nodules and inclusion criteria were the 
same in the two studies. In the present study, scores on the “goiter symptoms” and 
“general score” scales of the ThyPRO questionnaire showed a significant improvement 
from the first month and from sixth month onwards, respectively. The mean values of 
the scores on all 13 scales displayed a significant reduction from the sixth month 
onwards. In the present study, scores on each of the other scales did not change 
significantly. This could be due to LA does not affecting thyroid function. Indeed, 
  
changes in hyperthyroid symptoms, hypothyroid symptoms, eye symptoms, tiredness, 
cognitive problems, anxiety, depression and emotional susceptibility scales could be 
more closely related to changes in thyroid hormonal status.  
Our study yielded more short-term data on changes in QoL than that of Valcavi et al. 
[31]. However, our cohort of patients was smaller and follow-up was shorter.  
The main limitation of our study is its small population (n = 14) and short follow-up. 
Further studies, especially in a larger cohort of patients and over several years of 
follow-up, are necessary in order to confirm or disprove our data.  
In conclusion, LA is effective in reducing both nodule volume and neck symptoms. 
Moreover, the procedure is safe. In comparison to surgery, adverse events are few and 
mild. LA is well-tolerated by patients and the VAS score improves significantly in all 
patients. In our cohort of patients, the goiter scale, the general score and the mean 
value of ThyPRO scores improved significantly a few months after LA for benign non-
functioning thyroid nodules. 
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Table 1: patients demographic data.  
BMI = body mass index, L-T4 = levothyroxine ; MNG= multinodular goiter; UNG= 
uninodular goiter. 
 
Males / Females 2 / 12 
Age (years) (mean ± SD) 55 ± 10 
BMI (kg/m2) (mean ± SD) 25 ± 4 
L-T4 therapy (yes / no) 2 / 12 
Time since diagnosis (years) (mean ± SD) 7 ± 8 
MNG / UNG 6 / 8 
Location of the nodule (right lobe / left lobe) 10 / 6 
 
 
 
  
Table 2: volume of nodules and thyroid (mean ± SD) and volume reduction ratio  of 
nodules and thyroid at each time-point of the study. 
 
 Nodule 
volume  
(ml) 
Nodule volume 
reduction ratio 
(%) 
Thyroid 
volume  
(ml) 
Thyroid volume 
reduction ratio 
(%) 
Baseline 19 ± 14 - 32 ± 16 - 
1st month 11 ± 9   -42 28 ± 13 -12 
3rd month 9 ± 10 -57 23 ± 11 -28 
6th month 10 ± 11 -47 24 ± 12 -25 
12th month 9 ± 12 -57 24 ± 13 -25 
 
 
  
Table 3: thyroid function at each time-point of the study (mean ± SD). 
f-T3 = free T3, f-T4 = free T4, TSH = thyroid-stimulating hormone. 
 
 TSH 
(mIU/L) 
f-T3  
(pmol/L) 
f-T4  
(pmol/L) 
Thyroglobulin  
(μg/L) 
Baseline  1.76 ± 1.31 5.07 ± 0.74 14.69 ± 2.4 104.9 ± 83.5 
1st week 1.33 ± 0.97 5.24 ± 0.63 15.30 ± 1.8 452.2 ± 658.8 
1st month 1.25 ± 0.85 5.24 ± 0.55 14.95 ± 2.28 99.8 ± 93.7 
3rd month 1.28 ± 1.30 5.42 ± 0.54 15.37 ± 2.11 103.9 ± 228.9 
6th month 1.57 ± 1.29 5.07 ± 0.72 14.97 ± 1.71 107.9 ± 178 
12th month 1.07 ± 0.55 5.01 ± 0.64 15.24 ± 2.11 73.0 ± 57.8 
 
  
Table 4: ThyPRO scores (mean ± SD) on each scale at each time-point of the study. 
*= p<0.05 vs baseline; **= p<0.01 vs baseline 
 Baseline 1st 
month 
3rd 
month 
6th 
month 
12th 
month 
Goiter symptoms 23 ± 13 10 ± 8 * 9 ± 9 ** 8 ± 5 ** 7 ± 4 ** 
Hyperthyroidism 
symptoms 
13 ± 14 8 ± 14 9 ± 14 8 ± 9 2 ± 3 
Hypothyroidism 
symptoms 
9 ± 9 6 ± 6 8 ± 9 9 ± 10 7 ± 4 
Eye symptoms 9 ± 9 5 ± 7 6 ± 9 3 ± 5 1 ± 2 
Tiredness 34 ± 13 32 ± 13 31 ± 16 26 ± 10 21 ± 5 
Cognitive problems 11 ± 13 7 ± 12 13 ± 12 10 ± 8 6 ± 4 
Anxiety 17 ± 13 12 ± 11 13 ± 17 18 ± 13 17 ± 7 
Depression 26 ±15 19 ± 12 23 ± 15 17 ± 14 19 ± 9 
Emotional susceptibility 20 ±17 15 ± 13 14 ± 18 12 ± 10 10 ± 4 
Impaired social life 3 ±5 5 ± 9 3 ± 6 0 ± 2 0 ± 0 
Impaired daily life 5 ± 10 6 ± 8 4 ± 10 2 ± 4 0 ± 0 
Impaired sex life 6 ± 11 4 ± 8 3 ± 6 1 ± 4 3 ± 6 
Cosmetic complaints 6 ± 8 6 ± 11 4 ± 8 2 ± 4 1 ± 3 
General score 14 ± 19 7 ± 12 4 ± 13 0 ± 0 ** 0 ± 0 * 
Mean values 14 ± 7 10 ± 7 11 ± 9 9 ± 5 * 7 ± 1 * 
 
  
Figure 1: mean changes (columns) with SD (error bars) in nodule (full columns) and 
thyroid (empty columns) volume in milliliters (a) and percentage (b).  
Significance vs. baseline: *= p<0.05; **= p<0.01 
 
 
 
  
Figure 2: changes in the volume of a nodule at ultrasound scan at baseline (a, b); 12 
months after LA (c, d). Transverse (a, c) and longitudinal images (b, d). 
 
 
  
Figure 3: changes in VAS score, with mean score (squares) and SD (error bars). 
Significance vs. baseline: *= p<0.05; **= p<0.01 
 
 
  
Figure 4: significant changes in ThyPRO scale scores, expressed in mean percentages 
(boxes) and SD (error bars): a) goiter symptoms scale, b) general score scale, c) mean 
values.  
Significance vs. baseline: *= p<0.05; **= p<0.01 
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A comparison of laser with radiofrequency ablation for the treatment of benign 
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Introduction 
Over the last years, image-guided minimally-invasive techniques have been proposed 
to treat clinically relevant benign thyroid nodules (BTNs) [1,2]. Ultrasound-guided (US-
g) thermal ablation with laser or radiofrequency energy is increasingly being used for 
non-surgical management of symptomatic non-functioning thyroid nodules that are 
benign at cytological assessment [3]. Due to their debulking efficacy, substantial safety 
and low-cost as outpatient procedures, both laser ablation (LA) and radiofrequency 
ablation (RFA) are currently used in several thyroid referral centres. Microwave 
ablation (MWA) technique, on the other hand, represents an emerging but still not 
thoroughly assessed and well established ablative method for BNTs [4–6]. Numerous 
uncontrolled and prospective randomised controlled trials with different treatment 
algorithms have confirmed the clinical effectiveness and safety of LA [7–19] and of RFA 
in both solid thyroid nodules and in lesions with variable fluid component [20–27]. 
However, the reported series of LA usually included patients with larger thyroid 
nodules and the series of RFA included patients with a higher cyst component [2]. 
  
Thus, the results are difficult to be compared [28]. To date, only one review including 
meta-analysis [29] and a more recent paper on a small case series [30] have reported 
direct comparisons between the two techniques with contradictory conclusions. While 
the first study concludes that RFA is superior to LA, the second highlights a substantial 
equivalence of the two techniques when performed by operators with the same 
expertise. Thus, pending prospective comparative studies, we retrospectively 
compared LA and RFA outcomes in the treatment of benign thyroid nodules in a large 
cohort of patients treated at different centres in Italy. In order to minimise the effect 
of potential confounders or selection bias, patients of each group were matched by 
applying the one-to-one propensity score matching [31,32]. The aim of our study was 
to compare in real clinical practice the efficacy and safety of LA and RFA in the 
treatment of benign thyroid nodules. 
  
Methods 
 
Patients 
The institutional review board of each participating centre approved this retrospective 
study and waived the requirement for informed consent. All patients undergoing 
percutaneous thermal ablation for symptomatic BTNs from May 2009 to December 
2014 at eight thyroid referral centres were retrospectively considered for the study. 
Four of these centres had specific expertise in RF technique while four of them used 
laser technology. Then, four centres have only used RFA technique and four laser 
technology. In four centres the procedures were performed by endocrinologists, in 
three by interventional radiologists, and in one by surgeons. The patients had refused 
surgery or had poor surgical indications because of age, cardiovascular risk, respiratory 
failure or because they were not eligible for general anaesthesia. No patient had 
undergone ethanol sclerotherapy or other percutaneous minimally invasive therapies. 
Inclusion criteria were as follows: solid nodule (uniformly compact or nearly 
completely solid, with a liquid component not exceeding 30%); evidence at ultrasound 
examination of a single or of a dominant nodule, clearly detectable in a multinodular 
goitre; serum TSH and thyroid hormones within normal range; benign cytological 
examination (class II of the Bethesda classification system) [33] assessed by two 
separate FNAs; and presence of either local pressure symptoms or cosmetic concern. 
Patients were excluded from the treatment in case of suspicious or cytologically 
proven malignancy, altered serum TSH and thyroid hormones or coagulation disorders. 
 
  
Preoperative patient management 
A general consensus among centres for clinical, ultrasound and laboratory assessment 
was based on the international guidelines criteria [34,35]. Thyroid sonographic 
evaluation was conducted in all centres by means of a commercially available US 
scanner, equipped with a 7.5–13.0 MHz linear transducer. The nodule volume was 
calculated with the ellipsoid formula (V¼length_width_depth_0.525). Serum TSH, FT4 
and other laboratory controls were determined with commercially available 
immunoradiometric assay kits. Routine coagulation tests were performed before the 
procedure and included INR and platelet count. All centres operated according to the 
guidelines used for interventional procedures in other organs, such as liver, kidney or 
lung [36,37]. Only one session of treatment was scheduled for each nodule. 
 
Technique 
The treatment procedures followed those previously applied and published elsewhere 
[7]. Briefly, in the case of laser technique, the number of 21 gauge (G) applicators (up 
to four) to be inserted is based on nodule size. Under US-g the introducer needles, and 
subsequently the optic fibres, are inserted into the target thyroid nodule along its 
longest axis. Each treatment is performed using diode lasers with a fixedpower 
protocol (3 W). Each illumination time ranges from a minimum of 400 s to a maximum 
of 600 s to achieve a total energy delivery between 1200 and 1800 Joules per fibre. 
Depending on the size of the nodule, one to three consecutive illuminations are 
performed with a pullback technique during the same treatment session. For the 
radiofrequency technique, the procedure is based on the moving-shot technique as 
  
described elsewhere [21]. Under US-g electrode-needles with a caliber ranging from 17 
G to 19 G are inserted into the thyroid nodule along its short axis by using a trans-
isthmic approach. Different zones of the lesion were ablated sequentially by moving 
the position of the electrode tip. The electrode was initially positioned in the deepest 
part of the nodule and was moved into the central and finally the superficial areas of 
the lesion. During the manoeuvre, the output power ranges from 40 to 80 W, and the 
exposure time was calculated mainly on the appearance of a transient hyperechoic 
area in each of the different zones undergoing ablation [26,27]. The number of 
insertions depends on the nodule size. In different centres, the RFA procedures were 
performed by two endocrinologists with 4 and 6 years of experience, respectively, and 
by two interventional radiologists with 3 and 5 years of experience in the movingshot 
technique, respectively. Laser procedures were performed by three endocrinologists 
with 1, 6 and 10 years of experience, respectively, and by a surgeon with 7 years of 
experience. 
 
Data analysis 
The nodule population was classified, in agreement with the available data in the 
literature [11,14,27], into three groups according to the baseline volume. Nodules with 
initial volume _13 ml were defined as small, those between 13.1 to 30.0 ml as medium, 
and those >30.0 ml as large [38]. Preoperative characteristics, age, sex, ablation time, 
energy deployed per nodule and results in terms of percentage volume reduction 
(PVR) at 6 and 12 months in RFA and LA groups were compared overall and according 
to the baseline nodule volume. In each centre, operators performing the ablation were 
  
involved in the assessment of the results and data collection. Previous clinical evidence 
consistently demonstrated that the major volume reduction of nodules occurs within 
the first six months after treatment (with significant improvement of local symptoms), 
followed by a minor reduction from the sixth to the twelfth month [2,39]. On the basis, 
technical success was defined as a _50% volume reduction at 6 months after a single 
treatment session. Three treatment variables were considered and correlated with a 
successful outcome: baseline nodule volume, total ablation time (from the initial 
targeting of applicator(s) into thyroid nodule to the final assessment after treatment) 
and total energy delivered per treatment session. Finally, we compared major and 
minor complications of the two treatment modalities, classifying them according to the 
time of occurrence as intraprocedural (during the thermal session), postprocedural 
(within 24 h), periprocedural (within 30 days) and late complications [36,37]. To 
minimise the effect of potential confounders on selection bias, propensity scores were 
generated by using binary logistic regression to estimate the probability that a patient 
would undergo RFA instead of LA. Independent variables that entered into the 
propensity model included sex, age and baseline nodule volume. 
 
Statistical analysis 
Statistical analyses were performed using statistical software (SPSS, version 22.0 for 
Windows; SPSS, Chicago, Ill). All data were first analysed for normality of distribution 
using the Kolmogorov–Smirnov test of normality. One-to-one matching between the 
treatment groups was accomplished by using the nearest-neighbour matching method 
[31,32,40]. Briefly, the distribution of propensity scores was evaluated by treatment 
  
group to examine for sufficient overlap among the groups to ensure comparability. 
Continuous variables were expressed as mean ± SD, categorical variables displayed as 
frequencies and the appropriate parametric (student t-test) or non-parametric test 
(Mann–Whitney U-test or v2 test) was used to assess significance of the differences 
between subgroups. A p value of less than 0.05 was considered statistically significant. 
  
Results 
 
Baseline characteristics of LA and RFA groups Six hundred and one nodules in 601 
euthyroid patients were ablated percutaneously through US-g thermal therapy. Four 
hundred and forty-nine (mean age 57 ± 14) underwent LA while 152 (mean age, 57 ± 
14) underwent RFA. The baseline characteristics of all patients are shown in Table 1. A 
number of cases treated in each centre are reported in Figure 1(A,B). The mean total 
baseline volume of the nodules treated with LA did not show statistically significant 
differences (21.5 ± 16.5 vs. 24.6 ± 17.9 ml, respectively; p¼0.065) compared with 
nodules treated with RFA. Patients with baseline nodule volume>30 ml who 
underwent RFA were significantly older (65 ± 14 vs. 58 ± 15 years, respectively; 
p¼0.028) than those who underwent LA. The mean baseline nodule volume in group of 
patients with nodules_13 ml was significantly greater in patients who underwent RFA 
than in patients who underwent LA (9.9 ± 2.9 vs. 7.4 ± 3.1 ml, respectively; p<0.001) 
(Table 1).  
 
Volume reduction according to baseline nodule volume 
Mean nodule volume decreased from 21.5 ± 16.5 at baseline  to 8.7 ± 7.7 (p <0.001) 
and to 8.0 ± 7.2 ml (p<0.001) at 6 and 12 months, respectively, after treatment in 
patients who underwent LA. Mean nodule volume decreased from 24.5 ± 17.9 ml at 
baseline to 11.3 ± 10.7 (p<0.001) and to 9.9 ± 9.5 ml (p<0.001) at 6 and 12 months, 
respectively, after treatment (p<0.001) in patients who underwent RFA. There were no 
statistically significant differences between the two treatment groups. Volume 
  
reduction in nodules >30 ml at both 6 and 12 months was significantly higher (p¼0.003 
and p¼0.033, respectively) in LA group (from mean 45.1 ± 16.6 ml baseline volume to 
17.6 ± 9.8 ml and to 16.0 ± 9.3 ml, respectively) than in RFA group (from mean 49.0 ± 
20.3 ml baseline volume to 24.6 ± 13.3 ml and to 21.5 ± 11.5 ml, respectively). The 
total energy delivered per treatment/session was significantly higher in nodules 
treated with RFA than in nodules treated with LA (64.6 ± 58 vs. 5.8 ± 2.7 kJ, p¼0.001). 
There was no statistically significant difference in ablation time between the two 
techniques. All results are summarised in Table 1. 
 
Technical results 
Although not statistically significant, the rate of technical success was higher in LA- 
than in RFA-treated patients (75% vs. 69%; p¼0.197). The baseline volume was higher 
in PVR _50% group than in PVR <50% group (p¼0.006) in the LA-treated while this 
finding was not observed in the RFA treated patients. Total energy delivered was 
higher in PVR _50% group than in PVR <50% group, both in LA-treated patients 
(p¼0.033) and in RFA-treated patients (p¼0.010). Finally, ablation time was longer in 
the PVR _50% than in PVR <50% group, both in all study patients (p ¼0.001) and in only 
RFA treated-patients (p ¼0.002). Table 2 summarises all these data. Figure 1(A,B) 
shows the distribution of the number of patients with a nodule volume reduction 
higher or lower than 50% at 6 months in the LA (panel A) and in the RFA (panel B) 
groups according to the different centres/operators. In both groups, operators with 
interventional training (surgeons or interventional radiologists) had the highest rate of 
>50% volume reduction. 
  
Comparison of volume reduction rates between LA group and RFA group after one-to-
one propensity score matching 
We trimmed the sample by removing 325 patients (RFA, n¼14; LA, n¼311) with non-
overlapping propensity score distribution. Therefore, adjusted comparisons by 
propensity scores were based on data from 138 patients for each treatment arm. 
Confounding factors were well matched between the LA and RFA groups: mean age 57 
± 14 vs. 57 ± 13 (p¼0.932), baseline nodule volume 21.9 ± 13.3 vs. 21.5 ± 11.5 
(p¼0.760), and female subjects 69% vs. 72% (p ¼0.572), respectively. Therefore, after 
this matching the resulting two patient groups had similar baseline characteristics. 
After this adjustment, mean nodule reduction at 6 and 12 months was _67 ± 19% 
(mean volume 7.5 ± 6.6 ml) vs. _57 ± 21% (9.6 ± 7.5 ml) (p<0.001) and _70 ± 19% (6.6 ± 
6.2 ml) vs. _62 ± 22% (8.6 ± 7.8 ml) (p¼0.001) in LA vs. RFA group. Nodules with 
volume>30 ml had significantly higher percentage volume reduction at 6 and 12 
months in the LA group than in the RFA group (_70 ± 19% vs. 62 ± 22, p¼0.001). No 
difference in total ablation time was detected (17.7 ± 6.3 vs. 18.7 ± 13.6 min 
(p¼0.436), while a lower release of energy in the LA group compared to the RFA group 
was confirmed (6.1 ± 2.7 vs. 61.6 ± 51.4kJ, respectively; p¼0.001) (Table 3). According 
to the PVR_50% response, the rate of volume reduction was greater in LA than in RFA 
group (86% vs. 70% and 92% vs. 78%) at 6 and 12 months, respectively. In Figure 2, we 
report the mean nodule reduction at 6 and 12 months according to baseline nodule 
volume group in all patients before (A) and after (B) propensity score adjustment. 
Again, in both groups the propensity score-matching analysis confirmed the operators’ 
role in determining a volumetric reduction greater than 50% at six months. 
  
Complications 
No immediate or late changes in thyroid function were observed. Thyroid-stimulating 
hormone, (TSH) free triiodothyronine (FT3) and free thyroxine (FT4) serum levels 
remained stable. No significant changes were observed in anti-thyroglobulin (TgAb) 
and anti-thyroperoxidase (TPOAb) antibodies titres during follow up, except for a 
single patient with a large nodule who developed autoimmune hyperthyroidism six 
months after RF ablation. Table 4 reports the incidence of major and minor 
complications and side effects in both groups. 
  
Discussion 
 
Several case reports and prospective randomised trials have established the clinical 
effectiveness of US-g thermal ablation procedures for the management of 
symptomatic BTNs [39]. Presently, a still unresolved issue concerns the comparison of 
the two mainly used techniques – laser and RF – in terms of technique efficacy and 
safety in real clinical practice. One recent systematic review tried to compare the 
results of RFA and LA from the data of the published literature, and concluded that 
RFA appears to be superior to LA in reducing benign solid thyroid nodule volume [29]. 
However, in this paper, the considered studies had very small number of patients 
(range 10–21), papers regarding LA were all significantly older than paper regarding 
RFA, and 6 out of 8 considered papers on LA were performed by the same author. A 
more recent paper compared results of LA and RFA performed by the same equipe of 
operators, and found no significant differences among the two techniques, suggesting 
that the two techniques might be similarly effective when performed by operators 
with the same expertise. However, this study was based on a limited experience of a 
single equipe of operators [30]. For this reason, our comparative study was performed 
on a consecutive population of patients treated in thyroid referral centres and its 
outcomes reflect the clinical findings of the everyday activities of well-trained 
operators working in this field. To our knowledge, this is the first large retrospective 
cohort study to date which compares safety and technique efficacy of RFA and LA in 
the percutaneous treatment of benign solid thyroid nodules by using propensity score 
  
matching with power analysis and statistically simulating randomised controlled trials 
[31]. 
This study leads to some interesting considerations. The first is that both percutaneous 
thermal ablation procedures were highly effective in inducing a significant decrease in 
thyroid nodule volume. Both techniques were equally effective in small and medium 
size nodules, while the laser technique showed a slightly greater efficacy than RFA in 
nodules larger than 30 ml (Table 1 and Figure 2(A,B)). Based on previous studies on 
thyroid tissue and in other organs [13,41–43], this different outcome could be due to 
the simultaneous use of multiple (up to four) laser sources in large nodules, with a 
more homogeneous distribution of heat energy in the target area and thus with 
greater treatment efficacy. Moreover, with the trans-isthmic approach it might be 
more difficult to treat the deeper part of large nodules, which can be conversely easily 
reached by a direct puncture of the nodule on its long axis. After adjustment by the 
propensity score matching, the higher rate of PVR in the LA group for large thyroid 
nodules was confirmed (as represented in Figure 2(B) and in Table 3). Notably, both 
techniques produced a rather wide variability in nodule volume reduction (Figure 
3(A,B)). This results in a relevant overlap between the two procedures. Although the 
statistical analysis shows a significant difference between LA and RFA, in clinical 
practice the different efficacy of the two techniques seems to be of minor importance. 
A randomized controlled trial (RCT) could confirm this specific finding. To this end, we 
are currently conducting an ongoing Phase III trial and we are recruiting patients to 
prospectively assess the effectiveness and safety of LA compared to RFA 
  
(ClinicalTrials.gov identifier: NCT02714946) in order to avoid the potentially 
confounding bias present in this retrospective study. 
A second and the most relevant finding, as shown in Figure 1, is the role of the 
operator in determining the efficacy and the extent of nodule volume reduction. The 
influence of the operator experience on the treatment outcome was confirmed, 
regardless of whether laser light or radiofrequency energy was used. The proper 
targeting of nodules in close proximity to vital structures such as neck vessels, trachea 
and laryngeal nerve requires a good manual skill in placing the devices correctly in an 
anatomical region as small as the neck. This problem underscores the importance of 
appropriate training and learning curve, which should be longer for operators who are 
not confident with minimally invasive procedures. This issue should be better clarified 
by a study addressed to the learning curve of individual operators for thyroid 
minimally invasive techniques. 
Thirdly, we observed that to achieve a comparable volume reduction in small and 
medium size nodules, the operators used more energy (about ten times more) with 
the radiofrequency technique than with laser technology (Table 2 and Figure 2). This 
finding could be explained by the different modalities of production and distribution of 
thermal energy within the tissue to be ablated by means of the two techniques. The 
last data, however, do not seem to be relevant in clinical practice because they are 
inherent to the technique used but do not cause the undesired effects on thyroid 
tissue that are described in hepatic thermal ablation [44–46]. 
The two procedures appeared both safe and well tolerated, with a similar 
complications rate (Table 4). The easiness of use of techniques seems to be subjective 
  
and in most cases is dependent on the clinical circumstances and on the devices 
available in the institution where the operators work. 
Finally, since costs are becoming more and more important in decision making, may be 
useful to consider the costs of the two techniques. Taking into account the rental of 
generators in both techniques, the cost of a single laser applicator is about U.S.$250 
per session (in most cases two applicators are needed) while the cost of an RFA 
electrode is about U.S.$800 per session. Both treatments may be performed on 
outpatients by an operator and a nurse. In both procedures, the cost of dressings, 
including local anaesthetics and pain-killers, is quite low. 
Our study has some limitations. First, we used a retrospective approach; therefore, 
inherent selection bias was unavoidable, even with the propensity score analysis. 
Second, this was a multicentre study with only eight participating centres, even if each 
of them had a large volume of percutaneous RFA or LA ablation. Moreover, operators 
were involved in the results assessment and data collection, and some possible bias 
should be taken into account. Therefore, we believe that careful consideration is 
needed before generalizing our results to other settings. 
In summary, this study confirms the efficacy and safety in different clinical settings of 
US-g thermal ablation procedures consistently with previous reports. RFA and LA 
techniques seem to provide similar results, with a high success rate and low risk of 
major complications. The only difference was observed in the efficacy of LA in 
comparison with RFA in treatment of large size nodules. This finding seems to be, at 
least in part, due to the variable skill and experience of the operators. 
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Table 1. Baseline characteristics and results in all study patients according to baseline 
nodule volume group before propensity score matching. 
 
 
  
Table 2. Predictive factors for percentage volume reduction (PVR) at 6th month in all 
study patients and according to LA or RFA treatment before propensity score 
matching. 
 
 
  
Table 3. Results in all study patients according to baseline nodule volume group after 
propensity score matching. 
 
 
Table 4. Major, minor complications and side effects in each group of 138 patients. 
  
 
  
Figure 1: The figure shows the operator’s role in determining the extent of nodule 
volume reduction using laser light (A) or radiofrequency energy (B). 
 
 
  
Figure 2: The figure shows the mean nodule reduction at 6 months according to 
baseline nodule volume group in all patients before (A) and after (B) propensity score 
adjustment. After propensity score-matching analysis, the higher rate of PVR in LA 
group in comparison with RFA group, appears confirmed in large nodules (>30 ml) 
thyroid nodules, appears clearly confirmed. 
 
 
 
  
Figure 3: The figure shows the wide variability in volume reduction with both the 
techniques according to baseline nodule volume, both before (A) and after (B) 
propensity score adjustment. 
 
 
 
 
 
 
 
  
CHAPTER 5 
A case of thyroid cancer on the track of the radiofrequency electrode 30 months after 
percutaneous ablation.  
Oddo S, Spina B, Vellone VG, Giusti M.  
J Endocrinol Invest. 2017; 40: 101-102 
 
Dear Editor,  
a recent publication described a case of a full-thickness skin burn of the neck as a 
severe complication of percutaneous radiofrequency ablation (RFA) for a benign 
thyroid nodule [1]. We report what we believe is the second case of needle-track 
tumor seeding after RFA of a thyroid nodule [2]. 
This case involved a 74-year-old woman with negative oncological history and a 
symptomatic multi-nodular goiter: the predominant nodule (APxLLxCC diameters: 
37x37x45 mm; 34 mL) was solid, isoechoic and localized in the right lobe. Thyroid 
function was normal, calcitonin and thyroid autoimmunity were negative. The patient 
underwent a fine-needle aspiration biopsy (FNAB), which revealed a colloid nodular 
hyperplasia (Thy 2). As the woman refused thyroidectomy, we proposed RFA of the 
predominant nodule. After a second FNAB (Thy 2), RFA was performed by means of a 7 
cm, 19-Gauge electrode with a 1 cm active tip (Starmed, Seoul, Korea) and a moving-
shot technique with a delivered energy of 14151 Joules. 
Follow-up examination did not show any reduction of the nodule and, 30 months after 
RFA, an ultrasound scan revealed a hypoechoic extra-thyroid jugular median supra-
fascial lesion of about 14 mL (APxLLxCC diameters: 26x30x34 mm). FNAB on that lesion 
  
showed an hyperplastic, hypercellular with focal cytologic atypia (Thy 4), without 
BRAF, K-RAS or N-RAS mutations. Thyroidectomy, with excision of the extra-thyroid 
lesion, was performed.  
The histologic diagnosis of the RFA-treated nodule was of a follicular carcinoma with a 
minority component of papillary carcinoma (collision tumor). Immunohistochemistry 
proved positive for galectin-3 and cytokeratin 19 in the papillary component; these 
were negative in the follicular component; the extra-thyroid lesion was a medium-
differentiated follicular carcinoma; galectin-3 and cytokeratin 19 were negative. 
Revision of pre-RFA FNAB confirmed the Thy 2 diagnosis. 
As suggested by Lee et al. [2], there are three possibilities: an incidental malignant 
potential of the benign thyroid nodule, the RFA-induced transformation of cells, or a 
sampling error.     
Whether the risk of malignancy in thyroid nodules increases with size is debated, and 
the presence of cancer in Thy 2 has been described in about 6% of cases [3]. Moreover, 
2% of Thy 2 transform into carcinomas.  
We suppose that the extra-thyroid lesion was a dissemination of the follicular 
component of the thyroid carcinoma for the following reasons: (I) atypical site for 
metastasis; (II) it could not have been the canceration of an ectopic thyroid (not seen 
on US scan; histological examination revealed no residual normal tissue around the 
neoplasm); (III) tumor development corresponded to the insertion site of the electrode 
(trans-isthmic access); (IV) the moving-shot technique may increase the risk of seeding. 
Seeding of malignant cells after FNAB on thyroid nodules has been anedoctally 
reported in the literature;  in agreement with Lee et al. [2], we suppose that RFA, as 
  
already described in liver and kidney, could cause seeding of malignant cells in the 
thyroid. 
In conclusion, RFA is effective and safe, though in rare cases it can cause seeding of 
malignant cells from the nodule. 
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LEFT: histology of thyroid collision tumor of the right lobe: P) papillary component that 
is positive for cytokeratin 19 (left) and galectin-3 (right), F) follicular component that is 
negative for cytokeratin 19 (left) and galectin-3 (right); RIGHT: histology of extra-
thyroid nodule: only follicular pattern that is negative for cytokeratin 19 (left) and 
galectin-3 (right). 
 
 
 
 
 
  
CHAPTER 6 
A benign thyroid nodule unresponsive to radiofrequency ablation  treated with laser 
ablation. 
Oddo S, Balestra M, Vera L, Giusti M.  
Journal of Medical Case Reports. Under review 
 
Background 
Since 2010, practical guidelines have approved radiofrequency ablation (RFA) and laser 
ablation (LA) as possible therapeutic options for the treatment of benign symptomatic 
thyroid nodules in patients who refuse thyroidectomy or in those with comorbidities 
that contraindicate surgery [1, 2]. 
RFA and LA are safe and effective techniques for reducing nodule volume, neck 
symptoms and cosmetic complaints [3, 4].  
Therapeutic success is defined as a nodule reduction >50% from the baseline volume 
6-12 months after the procedure and is reportedly achieved in 67% and 81% of cases 
of LA and RFA, respectively, on 6-12-month follow-up [3, 4]. However, for unknown 
reasons, a percentage of nodules do not respond to thermal ablation. 
Our paper describes the first case in literature of a benign thyroid nodule treated 
unsuccessfully with RFA and afterwards treated with LA with a significant reduction of 
volume and symptoms at the neck. 
  
Case presentation 
A 41-year-old Caucasian female discovered  the presence of a mass at the neck 
palpation. Her family history was negative for thyroid illnesses, and she stated that she 
had no significant past medical history. The physical examination confirmed the 
presence of a soft mass in the right portion of the neck, mobile with swalling acts. The 
patient underwent a ultrasound (US)-scan, which showed a single, solid, isoechoic 
nodule of 12 mL (antero-posterior x latero-lateral x cranio-caudal diameters: 20 x 30 x 
40 millimeters) in the right lobe of the thyroid (figure 1a). The patient was 
symptomatic for neck discomfort, with a score of 6/10 on the visual analogic scale 
(VAS). Thyroid function was normal (TSH 1.81 mIU/L, f-T3 5.0 pmol/L, f-T4 14.12 
pmol/L); calcitonin was normal (<1 ng/L) and thyroid autoimmunity was negative (TPO-
Abs 18 U/mL). 
The patient underwent a fine-needle aspiration biopsy (FNAB), which revealed a 
colloid nodular hyperplasia with hyperplastic thyrocites and fluid colloid (Thy 2 
according to the British Thyroid Association). The patient refused lobectomy for fear 
about surgery, so we proposed RFA of the nodule. After a second FNAB (Thy 2 
according to the British Thyroid Association), a phoniatric evaluation, which excluded 
anomalies of  vocal cord motility, and an electrocardiogram, which excluded 
arrhythmias, as suggested by the Korean consensus statement [5], a single session of 
RFA was performed with trans-isthmic access and moving-shot technique [5], with a 
delivered energy of 41868 Joules (3489 J/mL) in a day-hospital regimen. RFA was 
performed by means of 7 cm, 18 Gauge electrodes with a 1 cm active tip, with the 
support of an ultrasound MyLab Five (Esaote, Genoa, Italy) with a 7.5 MHz linear probe 
  
(LA523). The radiofrequency generator used was an RF System Viva VRS01 (Starmed, 
Seoul, Korea) and the peristaltic pump was an R4S100 (Starmed, Seoul, Korea). 
Before RFA the patient underwent intravenous infusion of ketorolac (20 mg) and 
ranitidine (50 mg) diluted in 100 ml of 0.9% saline solution for 30 minutes. 
Subsequently, intravenous ketorolac (40 mg) and ranitidine (50 mg) were administered 
in 500 ml of 0.9% saline for about 5 hours (during and after thyroid RFA). A pre-
procedural local anesthesia with 2% lidocaine was carried out at the puncture site. The 
procedure was well-tolerated by the patient and there were no adverse events; after 
thyroid RFA, a compressive bandage and ice were applied to the neck and the patient 
received a domiciliary prescription for steroid administration (prednisone 25 mg for 3 
days, 12.5 mg for 3 days, 6.25 for 3 days) and gastric protection,At the time of the RFA, 
our operator had 1-year experience of this technique. 
During follow-up, the nodule  displayed only a modest and fugacious volume reduction 
and from the sixth month the nodule regrowth (figure 1b and 2a). The patient's neck 
discomfort persisted (figure 2a). 
Twenty-four months after RFA, as the patient again refused to undergo lobectomy, we 
proposed a single session of LA. This was performed by the same operator, who had 
with 1-year experience of this technique, by means of 2 fibres of 300 µm diameter 
inserted by means of a 21-Gauge Chiba-needle (ELESTA®, Calenzano, Italy), with one 
pull-back of 1 centimetre and a delivered energy of 5489 Joules (457 J/mL). LA was 
performed by means of a commercially available US scanner (Echo-laser X4®; Esaote, 
Genoa, Italy) equipped with a 7.5 MHz linear transducer (LA 332, Esaote®, Genoa, Italy) 
  
with a 1064 µm diode laser unit with an individual energy emission setting and an 
indipendent activation. The pre-procedural modalities were the same of RFA. 
The procedure was well-tolerated by the patient and there were no adverse events. At 
the time of the LA, our operator had 1-year experience of this technique. The patient 
referred a progressive improvement in neck symptoms and cosmetic complaints, and 
follow-up examinations showed a marked, progressive reduction in nodule volume 
(figure 1c and figure 2b). Thyroid function and thyroid autoimmunity remained 
unchanged after RFA and LA (table 1). 
  
Discussion 
Both RFA and LA are percutaneous techniques, and their efficacy in reducing thyroid 
nodule volume is reported to be similar [6]. Therapeutic success (nodule volume 
reduction >50%) is achieved in the majority of cases by both techniques [3, 4]. 
Some studies have identified factors that might predict a good response to RFA, 
though these are controversial: the small volume (<12 mL) of the nodule at the 
baseline [7], the absence of vascularization [8] the presence of a fluid component [9], 
the non-functioning status [10], and the presence of well-defined margins [4]. By 
contrast, a study by Papini et al. [3] found that baseline size, presence of goiter or US 
findings (like fluid component, halo, vascularization and calcifications) were not 
predictive factors of a volume decrease > 50% in thyroid nodules treated with LA. 
Our patient's thyroid nodule was smaller than 13 mL, non-functioning, well-defined, 
and free from vascularization; thus, there were no parameters that could predict the 
inefficacy of RFA. 
When therapy is not successful, another session of ablation may be proposed; in the 
second session, the same ablation procedure is generally performed [11]. This choice is 
probably determined by the availability of LA or RFA in each centre. 
In our centre, however, we had the possibility to perform both RFA and LA. We chose 
to perform LA after unsuccessful RFA because in our cohort of patients, we had already 
observed two cases in which the repetition of RFA had failed to yield significant results 
in nodules that had previously undergone an unsuccessful RFA procedure so we 
conjectured that certain nodules might be intrinsically resistant to necrosis when one 
ablation technique is undertaken, but might respond to the other ablation technique. 
  
Other possibility could be the inexperience of the operator in performing RFA 
compared to LA, but he performed RFA and LA with the same time of experience in 
both the procedures. 
In our case, the thyroid nodule, which had not responded to a single session of RFA, 
displayed an optimal response to a single session of LA. We excluded the possibility 
that the better response of the nodule to LA might have been due to greater operator 
experience of this technique, as our operator had the same length of experience of 
both techniques at the time when they were performed.  
  
Conclusions 
In our opinion, LA may be a viable option in patients with a thyroid nodule that does 
not respond to RFA and who refuse surgery or have comorbilities that contraindicate 
it. It would be useful to conduct a study on a large cohort of patients with an inefficient 
response to RFA or to LA who are subsequently treated with the other technique.     
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Table 1: thyroid function and autoimmunity at each time-point of the study. 
 
 TSH 
(mIU/L) 
(0.27-4.2) 
f-T3 
(pmol/L) 
(2.76-7.07) 
f-T4 
(pmol/L) 
(11.97-21.88) 
Calcitonin 
(ng/L) 
(<10) 
TPO-Abs 
(U/mL) 
(<100) 
Baseline RFA 1.81 5.00 14.12 <1 18 
3rd month 1.60 4.98 15.30 - 19 
6th month 1.43 5.20 14.35 - 25 
12th month 1.57 5.05 15.07 - 15 
24th month / 
Baseline LA 
1.61 5.30 14.78 - 26 
3rd month 1.47 5.12 15.03 - 30 
6th month 1.36 4.97 14.99 - 24 
12th month 1.89 5.00 15.12 - 19 
 
  
 
Figure 1. Ultrasound images of thyroid nodule.  
Figure “a” shows the thyroid nodule at the baseline; Figure “b” shows the thyroid 
nodule 24 months after radiofrequency ablation; Figure “c” shows the thyroid nodule 
12 months after laser ablation. 
 
  
 
Figure 2. Changes in volume of the nodule and in symptoms at the neck of the 
patient.  
Graph “a” shows changes in the thyroid nodule volume and symptoms at the neck by 
mean of the visual analogic scale (VAS) from baseline to 24 months after 
radiofrequency ablation (RFA); Graph “b”  shows changes in the thyroid nodule volume 
and symptoms at the neck by mean of VAS from baseline of laser ablation (LA) (24 
months after RFA) to 12 months after  
 
 
 
  
CHAPTER 7 
Other papers 
 
Five-year longitudinal evaluation of mild primary hyperparathyroidism - medical 
treatment versus clinical observation.  
Vera L, Accornero M, Dolcino M, Oddo S, Giusti M.  
Endokrynol Pol. 2014; 65: 456-463. 
 
Introduction 
Primary hyperparathyroidism (PHPT) is a disorder characterised by inappropriately 
high secretion of parathyroid hormone (PTH). PHPT has become a common disease, 
with an estimated prevalence of 1% of the general population and 3% in 
postmenopausal women [1], and an increasing incidence over the last few decades. 
PHPT is usually the result of a single over-active parathyroid gland as a result of 
adenoma, hyperplasia or cancer [2]. The clinical presentation has changed over the 
years: today, 80–85% of cases are asymptomatic [3]. 
A National Institutes of Health consensus panel has recognised two forms of the 
disease: asymptomatic and symptomatic [4]. The diagnosis is based on the clinical and 
objective picture, evaluation of serum calcium (S-Ca) and PTH. Preoperative 
localisation studies are required. 
Therapy may involve medical or surgical treatment, and many guidelines have been 
proposed over the years. Although parathyroidectomy (PTX) is regarded as the 
treatment of choice for patients with symptomatic hypercalcaemia or evidence of 
  
target organ damage [5], conservative management has been favoured in 
asymptomatic patients. In addition, in some cases surgery fails, in some it is 
contraindicated, and in others it is refused [6]. At the most recent International 
Workshop [7], the guidelines pointed out that there was no data to support the 
medical treatment of patients with mild PHPT. In general, it is recommended that 
patients who do not meet surgical criteria [7] be monitored closely. However, the 
validity of medical treatment is unanimously recognised. The prognosis of PHPT 
patients depends on the time-line of the diagnosis. 
The aims of our five-year study were: 1) to evaluate patients with PHPT during the 
course of different types of treatment; and 2) to evaluate quality of life (QoL) in PHPT 
subjects by means of several instruments, both self-rated and physician-administered. 
 
  
Material and methods 
Patients 
We longitudinally evaluated all patients (aged 22–90 years) with a history of PHPT in 
our endocrine unit from 2007–2011. Over the years, the number of patients 
progressively increased. Patients (N = 18) on cinacalcet were excluded from the study 
owing to their small number. The remaining study population was divided into three 
groups: 52 patients were on anti-resorptive therapy (bisphosphonate-treated group: 
alendronate 70 mg/week N = 22, risedronate 150 mg/month N = 13, ibandronate 150 
mg/month N = 11, clodronate 100 mg/week N = 6); 37 were not on any treatment 
(untreated group); and 50 were disease-free after surgery (surgery group). When 
required, patients underwent supplementation with vitamin D (< 25mmol/L = 2,000 
U/day, 25–50 mmol/L = 1,000 U/day, 50–75 mmol/L = 800 U/day, as reported in the 
guidelines SIOMMMS). Written informed consent was obtained from all participants. 
Study design 
Evaluation was based on clinical examination, neck ultrasonography, bone mineral 
density (BMD) and blood tests. S-Ca and PTH levels were recorded on each occasion. 
Serum phosphorus, 25hydroxy-vitaminD (25OHD) and 1.25dihydroxy-vitaminD 
(1.25OHD), creatinine, total and bone-specific alkaline-phosphatase (ALP), urinary 
cross-links and osteocalcin were measured annually. Finally, an Italian ad hoc 
parathyroid questionnaire (PQ) was administered to all patients, to evaluate their QoL. 
On entry to the study, a semistructured clinical interview was conducted by a 
psychiatrist. All subjects were then asked to complete the Italian version of the self-
rated Kellner symptom questionnaire (KSQ) [8]. 
  
Laboratory evaluations 
PTH was analysed by means of two chemiluminescence immunoassays (2007-2008: 
Immunolite2000, Diagnostic Products, San Juan Capistrano, CA, USA; from 2009: 
LIASON N-tactPTH, DIASorin, Saluggia, Italy). Reproducibility of the data yielded by the 
two methods was excellent. The reference range (r.r.) is 15–65 ng/L or < 36.8 ng/L. 
Creatinine (r.r., 44.0–115.0 μmol/L), S-Ca (2.1–2.7 mmol/L), phosphorus (0.8–1.4 
mmol/L), and ALP (98.0–280.0 U/L) levels were determined by means of fully 
automatic equipment (ModularP800, Roche Diagnostics). Evaluation of 25OHD was 
performed by means of a chemiluminescence method (LIAISON, DIASorin). A range of 
75–250 nmol/L was considered indicative of adequate vitamin D intake. Evaluation of 
1.25OHD (r.r. 47.6–150 pmol/L) was performed by radioimmunoassay 
(Immunodiagnostic Systems). Osteocalcin (r.r. 0.5–7.0 ng/mL) was measured by means 
of an immunochemiluminescence method (Nichols). 
Urinary cross-links (expressed as the molar ratio of creatinine) were measured by high-
performance liquid chromatography (BioRad, Milan, Italy). 
Imaging 
Colour-Doppler neck ultrasonography (AU5Idea and MyLabFive; Esaote, Genoa, Italy) 
was performed by means of a device equipped with a linear 7.5–10 MHz probe. When 
indicated, fine-needle aspiration was performed and PTH was evaluated in fine-needle 
washing in order to locate hyperfunctioning parathyroid tissue [9, 10]. BMD (gr/cm2) 
in the lumbar spine and total hip was measured in the antero-posterior direction by 
means of a dual-energy X-ray absorptiometry technique (DXA) using Hologic 
instruments (QDR1500 and DQR4500, Bedford, MA). BMD was expressed as a T-score. 
  
The so-called standard deviation (SD) scores were calculated from the following 
equation: T-score = (BMD measured–BMD of a sex- and age-matched population)/SD. 
DXA was also evaluated at the baseline and each year. 
Survey measurements 
The ad hoc PQ was prepared as a simplified version of the medical outcome study 36-
item short-form survey (SF-36), which is a well-validated measure of general health 
status [11]. PQ comprised 39 questions, grouped into eight items designed to explore 
changes in general health perception, physical function, presence/absence of physical 
pain, social relations, mental health, osteoarticular pain, tiredness or vitality, and 
specific symptoms.  
PQ was scored by assigning one point for each negative reply (no physical or mental 
changes) and two points for each positive reply (physical or mental changes). The total 
score ranges from 39-78 [12]. 
The self-rated KSQ had already been used by us [12] and others [13] in similar studies. 
KSQ comprises eight subscales. The items anxiety, depression, somatization and 
hostility evaluate the degree of psychological discomfort or lack of well-being on a 
numerical scale ranging from 0–23 for each item. The higher the score, the lower the 
QoL. 
Statistical analysis 
In accordance with the classification of the WHO, osteoporosis was defined as a T-
score < –2.5 and osteopenia as a T-score between –2.5 and –1.0. Data was analysed by 
means of GraphPad Prism for Windows (Version4.0; GraphPad Software, San Diego, 
CA, USA). All values are expressed as mean ± standard error of mean (SEM) unless 
  
indicated otherwise. To evaluate changes in experimental parameters during the five-
year study, the non-parametric Kruskal-Wallis analysis of variance (ANOVA), followed 
by Dunn’s Multiple Comparison test, was used. To compare absolute and percentage 
data, Mann-Whitney and Chi-square tests were used.  
Correlation analyses between variables were carried out by means of the Spearman 
correlation. Data below the functional sensitivity or above the standard curve of the 
assays were analysed for statistical purposes by using the functional sensitivity value or 
the maximal value of the standard curve. Significance was taken as P-value ≤ 0.05. 
  
Results 
Clinical data 
In total, 157 patients with PHPT were followed up. Inter-group comparison by means 
of ANOVA revealed no significant differences in age (65.2 ± 14.0 years ± SD; P = 0.07), 
female:male ratio, or smoking. 
In the study population, mean body mass index (BMI) was 28.8 ± 5.2 kg/m2. Similar 
numbers of patients were overweight (BMI = 25–30 kg/m2) in the three study groups 
(patients with/without therapy, N = 38, 44%, and surgery group, N = 26, 52%). Eighty-
three patients underwent one or more PTX. Histology revealed parathyroid adenoma 
in most cases (N = 66; 79.5%) or hyperplasia (N = 7; 8.4%), and parathyroid carcinomas 
in three patients; histopathology data from the remaining (N = 10) patients could not 
be retrieved. About 50% of no-PTX patients (N = 37) were already symptomatic at the 
time of diagnosis, while 48% (N = 40) of those who had undergone surgery were 
symptomatic. At the time of diagnosis, 83 patients were symptomatic for kidney 
stones (N = 37), bone and joint pains (N = 24), osteoporosis (N = 23), pathological 
fractures (N = 5), and pancreatitis (N = 2). 
Laboratory data 
The untreated group and the bisphosphonate-treated group showed similar reductions 
in S-Ca and PTH concentrations over the five-year follow-up. However, both groups 
differed significantly from the surgery group: PTH levels (P = 0.05) in the untreated 
group (P = 0.01) were significantly higher than in the surgery group; S-Ca levels (P = 
0.0001) were lower in the surgery group than in the other two groups (Fig. 1). 
  
In all PTX patients, there was a significant difference (P < 0.001) between pre-surgical 
and post-surgical S-Ca levels. However, while PTH levels remained essentially 
unchanged in the bisphosphonate-treated group before and after the initiation of drug 
therapy, serum levels of the hormone were significantly (P < 0.001) reduced after PTX. 
Over the five-year study period, a significant reduction in PTH levels was seen only in 
the surgery group (P < 0.01); in the bisphosphonate-treated group, PTH levels tended 
to remain stable. A slight, non-significant increase in PTH levels was found in the 
untreated group. Similarly, S-Ca levels showed a significant reduction only in the 
surgery group (P < 0.05). 
On final evaluation, other biochemical indices did not differ significantly among the 
three groups. Finally, 48 (28.9%) patients showed Vitamin D deficiency (VDD) (25OHD < 
50 nmol/L). These subjects received replacement treatment with cholecalciferol 
(bisphosphonate treated group N = 33, mean dose 822.5 ± 158.6 U/day; surgery group 
N = 27, mean dose 737.5 ± 181.3 U/day; untreated group N = 16, mean dose 896.1 ± 
296.1 U/day). Only the surgery group showed significantly lower 1.25OHD levels than 
the untreated group (P = 0.001).  
Instrumental data 
Each year, ultrasonography was used to search for any sites of parathyroid tissue 
(Table I). 
BMD at the spinal level was not significantly different among the three groups of 
subjects (P = 0.1). 
T-scores were mildly, but not significantly, increased in the lumbar spine and 
unchanged at the femur level five years after observation or therapy. 
  
Quality of life 
No significant differences in QoL scores emerged among the three groups of subjects 
(score: bisphosphonate- treated group 60.3 ± 8.9; untreated group 53.7 ± 17.9; surgery 
group 48.0 ± 6.7; ANOVA, P = 0.06). In the surgery group, however, QoL improved 
significantly after PTX (Wilcoxon, P = 0.05) (Fig. 2). Among PTX patients, 76% were 
satisfied with their PTX. 
In semi-structured interviews of 28 subjects (21 females/seven males, age 63.4 ± 15.7 
years), the psychiatric evaluation performed did not detect any improvement in 
psychopathology. In the majority of cases in which psychopathology was present, this 
was minor (anxiety, anxiety-depression, reactive depression); it was major in four (3%) 
patients (N = 1 potomania or psychogenic polydipsia; N = 1 panic attacks, N = 2 major 
depression). Concomitant psychopathological events proved to be more frequent in 
women (males N = 2, females N = 14). The overall scores of the items on the self-rated 
KSQ were: anxiety 7.7 ± 3.5, depression 7.2 ± 5.3, somatisation 9.9 ± 6.1, and hostility 
4.9 ± 4.8. The correlations between age and KSQ scores, and between PTH and KSQ 
scores, were not statistically significant, nor was the correlation between KSQ and the 
duration (in months) of disease. No significant difference in KSQ scores emerged 
between females and males. 
 
  
Discussion 
Epidemiological considerations 
The mean age of PTX patients was lower than that of the other groups. This is 
compatible with the fact that older people tend to have more co-morbidities 
(contraindications for surgery) and with the guidelines [7], which state that operable 
patients should be < 50 years old. 
In our study, as in numerous epidemiological studies [10], PHPT was seen to be more 
frequent in females (N = 126, 77%) than in males (23%). Adenomas accounted for the 
majority of cases. These findings reflect the normal histological distribution of PHPT, 
which is supported by a solitary adenoma in 85-90% of cases [14]. 
BMI was higher in PTX patients. The reason for this is unclear. Finally, although 
smoking is a risk factor for osteoporosis, there was no significant difference between 
the number of smokers/past-smokers and non-smokers in our study. 
Considerations on treatments 
In the PTX patients, in agreement with previous evidence [15], we recorded a high 
surgical success rate. 
However, in many patients, PTH concentration remained elevated (Fig. 3); these 
findings are in line with those of the literature, although this is usually only seen in 20% 
of patients or less. It is also possible that some of these patients may have been 
suffering from VDD: vitamin D supplementation after PTX can reduce the incidence of 
increased PTH. In our series, the untreated patients had higher than average S-Ca 
values over time, while in the majority of our patients PTH remained stable or 
decreased over the five-year follow-up. As previously demonstrated [6], 
  
bisphosphonates do not normalise the levels of S-Ca and PTH. Likewise, in our series, 
all indices of bone metabolism differed only slightly in the bisphosphonate-treated 
group. Bisphosphonates are known to be effective in reducing bone turnover in PHPT 
patients [16]. However, we did not detect a significant difference in BMD in the 
subgroup treated. More recent data suggests that patients who have normal S-Ca 
levels after PTX, but elevated PTH, show no improvement in BMD comparatively [17]. 
This could explain why patients in all three groups displayed the same BMD changes. 
Thus, medical management is a helpful alternative to PTX in patients for whom surgery 
is contraindicated or refused and in those patients with PHPT that relapses after 
surgery. Medical treatment is based on the use of bisphosphonates, oestrogens, 
modulators of oestrogen receptors and calciomimetics [18]. Antiresorptive therapy 
may be an effective therapeutic approach in those patients with low BMD, in order to 
prevent further bone loss and to reduce the risk of fracture [19]. Moreover, a recent 
meta-analysis concluded that the effects of PTX and bisphosphonates were similar in 
mild PHPT [20]. Furthermore, PHPT patients have slightly lower 25OHD levels than 
controls, despite supplementation. 
Indeed, PTH induces renal conversion of 25OHD to 1.25OHD; integration may 
therefore require higher doses than in healthy subjects. 
However, we recommend vitamin D substitution before a final decision on treatment 
is made. Evidence that treatment with vitamin D reduces PTH levels and bone turnover 
in mild PHPT has been provided by case studies and uncontrolled/controlled cohort 
studies.  
 
  
Quality of life 
The clinical presentation of mild PHPT may include non-specific symptoms [21] that 
may affect QoL. In recent years, interest in QoL has grown in some endocrinological 
fields. Randomised studies have indicated beneficial effects of surgery on QoL, as 
surveyed by the SF-36; however, these effects have been minor and inconsistent, and 
the potential placebo effect of the surgery can never be ruled out [22]. One obstacle to 
evaluating illness perception in patients with PHPT is the current lack of developed 
questionnaires.  
With regard to the outcome of PHPT patients, it has not been specified that ad hoc SF-
36 and Hamilton tests should be administrated before and after PTX. Our ad hoc PQ 
had been prepared to measure general health status and specific symptoms of PHPT. 
Our data shows that persistence of the disease was variable in the different groups. 
However, we noted that QoL only improved in the surgery group. Indeed, over five 
years, we documented an improvement in somatic and psychological symptoms 
related to the presence of disease. 
Limitations 
Several limitations of our study have to be carefully considered, the first being the 
number of patients, which was somewhat lower than in other studies in the literature. 
However, over the years, the number of patients progressively increased and follow-up 
has now reached five years. 
A second major limitation is related to the difficulty of randomising patients, as several 
types of treatment overlapped in the same subjects.  
  
From a technological point of view, BMD was compared at the spine. Although the 
wrist is the first site of osteoporosis in PHPT, wrist assessment was rarely performed in 
most patients. 
 
  
Conclusions 
This study provided up-to-date information in terms of biochemical progression on the 
natural history of PHPT patients. No significant differences emerged between anti-
resorptive therapy and observation only. It is not yet possible to assess the effect of 
pharmacological treatments on QoL in statistical terms, although QoL appeared to 
worsen in our bisphosphonate-treated patients. However, the number of medically 
treated PHPT patients is increasing as a result of the review of surgical indications, the 
increased incidence of diagnose in asymptomatic patients, and the development of 
new drug therapies. 
 
  
References 
1. Yu N, Leese GP, Smith D et al. The natural history of treated and untreated 
primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study. 
Quart J Med 2011; 104: 513–521. 
2. Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145–158. 
3. Rubin MR, Bilezikian JP, McMahon DJ et al. The natural history of primary 
hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin 
Endocrinol Metab 2008; 93: 3462–3470. 
4. Bilezikian JP, Potts JTJr, Fuleihan Gel-H et al. Summary statement from a workshop 
on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J 
Clin Endocrinol Metab 2002; 87: 5353–5361. 
5. Macfarlane DP, Yu N, Donnan PT et al. Should ‘Mild Primary Hyperparathyroidism’ 
be reclassified as ‘insidious’: is it time to reconsider? Clinical Endocrinol 2011; 75: 730–
737. 
6. Faggiano A, Di Somma C, Ramundo V et al. Cinacalcet hydrochloride in combination 
with alendronate normalizes hypercalcemia and improves bone mineral density in 
patients with primary hyperparathyroidism. Endocr 2011; 39: 283–287. 
7. Bilezikian JP, Khan AA, Potts JTJr. Guidelines for the management of asymptomatic 
primary hyperparathyroidism: summary statement from the third international 
workshop. J Clin Endocrinol Metab 2009; 94: 335–339. 
8. Fava GA, Kellner R. Versione Italiana del Symptoms Questionnaire di Kellner. In: 
Canestrari R (ed.). Nuovi metodi in Psicometria. Firenze 1982: 51–64. 
  
9. Giusti M, Dolcino M, Vera L et al. Institutional experience of PTH evaluation on fine-
needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. J 
Zhejiang Univ Sci B 2009; 10: 323–330. 
10. Abdelghani R, Noureldine S, Abbas A et al. The diagnostic value of parathyroid 
hormone washout after fine-needle aspiration of suspicious cervical lesions in patients 
with hyperparathyroidism. Laryngoscope 2013; 123: 1310–1313. 
11. Ware JE, Sherbourne CD. The MOS 36-item short-form healthy survey (SF-36). I. 
Conceptual framework and item selection. Med Care 1992; 30: 473–483. 
12. Giusti M, Melle G, Fenocchio M et al. Five-year longitudinal evaluation of quality of 
life in a cohort of patients with differentiated thyroid carcinoma. J Zhejiang Univ Sci B 
2011; 12: 163–173. 
13. Lee J, Yun MJ, Nam KH et al. Quality of life and effectiveness comparisons of 
thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-
stimulating hormone administration for low-dose radioiodine remnant ablation of 
differentiated thyroid carcinoma. Thyroid 2010; 20: 173–179. 
14. Ruda JM, Hollenbeak CS, Stack BC. A systematic review of the diagnosis and 
treatment of primary hyperparathyroidism from 1995 to 2003. Otoryngol Head Neck 
Surg 2005; 132: 359. 
15. Udelsman R, Pasieka JL, Sturgeon C et al. Surgery for asymptomatic primary 
hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol 
Metab 2009; 94: 366–372. 
  
16. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary 
hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol 
Metab 2009; 94: 373–381. 
17. Ambrogini E, Cetani F, Cianferotti L et al. Surgery or surveillance for mild 
asymptomatic primary hyperparathyroidism: a prospective randomized clinical trial. J 
Clin Endocrinol Metab 2007; 92: 3114–3121. 
18. Marcocci C, Cetani F. Clinical practice. Primary hyperparathyroidism. N Engl J Med 
2011; 365: 2389–2397. 
19. Bollerslev J, Marcocci C, Sosa M et al. Current evidence for recommendation of 
surgery, medical treatment and vitamin D repletion in mild primary 
hyperparathyroidism. Eur J Endocrinol 2011; 165: 851–864. 
20. Sankaran S, Gamble G, Bolland M et al. Skeletal effects of interventions in mild 
primary hyperparathyroidism: a metaanalysis. J Clin Endocrinol Metab 2010; 95: 1653–
1662. 
21. Silverberg SJ, Lewiecki EM, Mosekilde L et al. Presentation of asymptomatic primary 
hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol 
Metab 2009; 94: 351–365. 
22. Perrier ND, Balachandran D, Wefel JS et al. Prospective, randomized, controlled trial 
of parathyroidectomy versus observation in patients with ‘‘asymptomatic’’ primary 
hyperparathyroidism. Surgery 2009; 146: 1116–1122. 
 
 
 
  
Table 1: Clinical, biochemical and instrumental parameters in all groups of patients 
on initial evaluation and on last follow-up evaluation (5 years).  
Data are expressed as mean ± SD unless otherwise specified. SD — standard deviation; 
BMI — body mass index; S-Ca — serum calcium; PTH — parathyroid hormone; ALP — 
alkaline phosphatase; 25OHD — 25-hydroxyvitamin D; 1,25OHD — 1.25dihydroxy-
vitamin D; Tx — thyroidectomy; UNG — uninodular goitre; MNG — multinodular 
goitre; NS — not significant. 
 
 
 
  
Figure 1: PTH and S-Ca levels in the surgery group (subjects deemed disease-free 
after surgery, N = 50), untreated group (patients without medical therapy or surgery, 
N = 37), and bisphosphonate-treated group (patients on anti-resorptive treatment 
with bisphosphonates, N = 52).  
PTH displayed a significant difference (ANOVA P<0.05) etween patients deemed 
disease-free after surgery and those without any therapy (a); regarding S-Ca, 
significant differences (ANOVA P = 0.001) emerged between patients deemed disease-
free after surgery and those without therapy (a) and between patients deemed 
disease-free after surgery and those on bisphosphonate therapy (b). 
 
 
 
  
Figure 2: Evaluation of pre- and post-surgery QoL by means of SF-36 scores in the 
three groups of subjects studied.  
A statistically significant difference was seen only in the surgery group (patients 
deemed disease-free after surgery). 
 
 
  
Figure 3: Distribution of prognoses in PHPT patients who underwent surgery.  
Both S-Ca and PTH concentrations normalised postoperatively in only 50.6%. In 
patients who underwent surgery, the clinical course and S-Ca levels prompted us to 
define the 8% of patients with hypercalcemia as ‘not cured’. In many patients (41.4%), 
S-Ca reverted to the normal range, while serum PTH concentration remained elevated. 
 
 
 
 
  
CHAPTER 7 
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Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and 
review of the literature.  
Vera L, Oddo S, Di Iorgi N, Bentivoglio G, Giusti M.  
J Med Case Rep. 2016; 10: 361. 
 
Background 
Primary hyperparathyroidism (PHPT) is typically a disease of middle-aged and older 
women. A recent analysis of a large health system database reported the incidence of 
PHPT to be 4.7 to 6.2 cases per 100,000 person-years in women of reproductive age 
(20 to 39 years) [1]. PHPT usually runs a relatively benign clinical course. By contrast, 
during pregnancy PHPT may have serious clinical implications [2], with rates of 
maternal complications, fetal complications, and fetal/neonatal mortality being 
estimated at 67 %, 80 % and 30 %, respectively [2, 3]. It is therefore important to 
recognize this pathology during pregnancy. This is not simple, however, owing to its 
aspecific presentation [3]. The most frequent complications are hyperemesis, pre-
eclampsia, nephrolithiasis, pancreatitis, hypercalcemic crisis, intrauterine growth 
retardation, preterm labor, neonatal tetany, and neonatal death [2–4]. Although the 
pregnancy may develop uneventfully, severe fetal/neonatal complications have been 
reported even in cases of mild PHPT. The optimal management of PHPT during 
pregnancy needs to be individualized. Most authors advocate parathyroidectomy (PTx) 
  
as the treatment of choice [2]. Surgery should be performed in the second trimester 
[3]. The safety of surgery in the first and third trimesters is debated because of the 
associated risks for the fetus [5]. The efficacy and safety of various modes of medical 
treatment for PHPT in pregnancy are largely unknown. So far, only hydration and 
calcitonin have emerged as safe treatments [5], although both will lower serum 
calcium (S-Ca) only temporarily. Bisphosphonates cross the placenta; they should 
therefore only be used in emergencies as a short-term intervention prior to surgery 
[6]. Calcimimetics are effective in reducing S-Ca in PHPT; however, they have rarely 
been used in pregnancy [7]. We describe a case of PHPT in pregnancy that was treated 
with cinacalcet. 
 
  
Case presentation 
We report the case of a 34-year-old white woman with a 5-year history of 
nephrolithiasis, who was referred to the Department of Endocrinology after having 
undergone a previous endoscopic treatment. A biochemistry evaluation revealed 
elevated S-Ca and parathyroid hormone (PTH) levels, consistent with severe PHPT. All 
data from the basic evaluation are reported in Table 1. She had no family history of 
hypercalcemia or other factors suggestive of multiple endocrine neoplasia (MEN) 
syndrome. Given her young age, genetic testing was performed, which excluded MEN1 
mutation. On examination, no mass was palpable in her neck. Neck imaging revealed 
no pathological parathyroid tissue: neck ultrasound, technetium-99m (99mTc) 
sestamibi scan, and single-photon emission computed tomography-computed 
tomography (SPECT-CT). Neck ultrasound showed a small nodule of 10 mm in her right 
thyroid lobe. Her bone density is below the expected range (Z-scores of −1.2 and −1.3 
at her spine and total hip, respectively). An abdominal ultrasound confirmed the 
bilateral presence of kidney stones. Oral hydration, cholecalciferol (600 U/day), 
vitamin C, and cinacalcet were started, but calcimimetic therapy was poorly tolerated. 
She became pregnant 17 months later while on therapy. 
Given the unknown teratogenic effects of cinacalcet in pregnancy, the calcimimetic 
was discontinued. Cholecalciferol was continued to 1200 U daily. During pregnancy, 
she presented two to three times per week  for saline infusions administered 
intravenously (sodium chloride, NaCl, 0.9 % 1000 ml two to three times per week) 
associated with oral hydration at home, but her S-Ca level was not controlled. 
Conversely, her PTH levels decreased (Table 2). Parathyroid re-exploration was 
  
performed in her tenth week of gestation. A nodular area was found at the inferior 
pole of the left lobe; the location and the sonographic appearance were typical of 
parathyroid adenoma. Fine-needle washing after aspiration biopsy (PTH-FNAB) was 
therefore carried out on both nodules. A cytological examination of the left nodules 
was not diagnostic, but the PTH-FNAB confirmed the thyroidal nature of the nodules: 
thyroglobulin-fine-needle aspiration biopsy (FNAB) 41334.0 μg/l, calcitonin-FNAB 6.8 
ng/l, and PTHFNAB 4.0 ng/l. The right nodule was a colloid nodule, which was classified 
according to the British Thyroid Association as Thy2: thyroglobulin-FNAB 23690.0 μg/l, 
calcitonin-FNAB 6.3 ng/l, and PTH-FNAB 4.0 ng/l. Exploratory surgery was proposed in 
her second trimester of pregnancy, but was refused and postponed to the postpartum 
period. Options for medical management were therefore explored. In her 24th week of 
gestation, daily treatment with cinacalcet (15 to 30 mg/day orally) was restarted, but 
nausea and hyperemesis ensued. 
The combination of calcimimetic and intravenously administered hydration resulted in 
a small decrease in her S-Ca (Table 2). However, in her 25th week, an episode of renal 
pain due to left nephrolithiasis occurred. Her renal function was normal, as was her 
electrocardiogram-monitored cardiac function. She was hospitalized in her 30th week 
of pregnancy for a non-serious spontaneous rupture of the membranes. A preterm 
delivery was decided upon. In her 32nd week of pregnancy, a cesarean section was 
carried out, and a baby boy was delivered. Postpartum, she discontinued cinacalcet in 
order to start breastfeeding. She was discharged on postoperative day 3, as is normal. 
A blood test 8 weeks after her cesarean section revealed elevated S-Ca and PTH levels, 
as noted in her prepregnancy period. Breastfeeding was discontinued and cinacalcet 
  
was restarted. The time-course of her S-Ca during pregnancy and her puerperium are 
reported in Fig. 1. 
One year after delivery, she underwent surgical exploration of her neck without 
further localization studies. Ten minutes after surgical removal of her left upper 
parathyroid gland (1.2 cm), her level of intraoperative PTH was 22 pg/ml. One day after 
PTx, her S-Ca levels were 2.22 mmol/L. Histology confirmed the diagnosis of adenoma 
of the parathyroid gland. 
The neonate 
Ultrasound scans in her first and second trimesters revealed normal fetal 
development. Immediately after delivery, the baby boy (weight 2.03 kg; length 45.0 
cm; head circumference 31.7 cm, Apgar score 8 to 9) was transferred to our neonatal 
intensive care unit. The baby boy had hyperphosphatemia with serum phosphorous (S-
P) of 7.94 mmol/l, hypocalcemia with ionized calcium (Ca++) of 1.12 mmol/l, and low 
PTH (17.0 ng/l); a picture compatible with hypoparathyroidism due to maternal 
hyperparathyroidism. Therefore, oral calcium gluconate 10 % (3 ml×7/day = 100 
mg/kg) and vitamin D (ergocalciferol, two drops/day and alfacalcidol, two drops/day) 
in milk feed were started. A mild episode of neonatal tetany occurred in week 4. After 
6 weeks, calcium supplementation was stopped and serum Ca++ was stable (Ca++ 1.13 
mmol/l; S-Ca 3.61 mmol/l). His PTH (38.0 ng/l) and S-P (7.12 mmol/l) were in the 
normal range. The time-course of Ca++ (in the first 30 days postpartum) is reported in 
Fig. 2. 
 
 
  
Discussion 
During pregnancy, the calcium metabolism is altered in order to supply calcium to the 
fetus. Although S-Ca may decrease owing to lower levels of albumin, Ca++ remains 
constant. In order to meet fetal needs, intestinal calcium absorption doubles under 
mediation by calcitriol, prolactin, and placental lactogen. There is a compensatory 
increase in renal calcium excretion, which allows the mother to remain eucalcemic. By 
contrast, in our case, S-Ca increased considerably, while urinary calcium remained in 
the normal range, probably owing to a dilution effect induced by forced hydration. 
Changes in PTH, PTH-related protein (PTHrP), calcitonin, and calcitriol may occur 
throughout pregnancy, but typically do not produce clinically significant perturbations 
in calcium balance [8]. 
Pathologic alterations in calcium metabolism during pregnancy are uncommon, but 
include PHPT, milkalkali syndrome or PTHrP-mediated hypercalcemia [9]. 
During pregnancy and the puerperium, sources of PTHrP include underlying 
malignancy, placenta, and mammary tissue during lactation: cases have been reported 
of hypercalcemic crises attributable to each of these sources [10]. Since PTH levels are 
not proportionately high, the poor control of hypercalcemia may be partly a result of 
PTHrP. After delivery, hypercalcemia may acutely worsen owing to loss of placental 
shunting of calcium away from the maternal circulation; alternatively, S-Ca levels may 
decrease if the placenta was a source of PTHrP, which may have been a factor in our 
case. 
As demonstrated by our patient, PHPT may put the mother and fetus at risk of more 
severe complications; this case also illustrates the fact that maternal hypercalcemia 
  
can cause neonatal hypoparathyroidism, which are manifested in only 12 % of 
neonates [11]. 
Considerations on imaging The usual techniques for detecting parathyroid adenomas 
or hyperplasias are not recommended in pregnancy. Technetium (Tc) and 99mTc 
sestamibi scintigraphy should be avoided, owing to the risk of ionizing radiation for the  
fetus. The effects of fetal irradiation are divided into deterministic effects (caused by 
damage to a number of cells in tissues) and stochastic effects (caused by mutations in 
cells). McMullen et al. [12] have described the use of functional imaging in pregnancy 
while appropriately shielding the fetus; in our case, however, such an approach would 
have been very unlikely to yield a positive result, as the SPECT-CT performed shortly 
before the pregnancy was negative. In addition, McMullen et al. [12] claimed that 
99mTc sestamibi imaging may be used safely to visualize the parathyroid glands only 
after negative cervical explorations, which our patient had refused. Thus, neck 
ultrasound is currently the first-line investigation for locating parathyroid diseases 
during pregnancy (sensitivity of 69 %, specificity of 94 %) [3, 13]. The failure of imaging 
is most unusual in patients with S-Ca levels higher than 3 mmol/L, as in our case. In our 
case, an ultrasonography examination was supplemented by PTH-FNAB. The use of this 
type of examination in the diagnosis of PHPT is debated [14]. In the present case, 
however, it was necessary in order to tackle the differential diagnosis between PHPT 
and thyroid nodules and then to decide whether to undertake mini-invasive surgery 
(recommended) or exploratory surgery (more invasive and therefore not 
recommended in pregnancy) [12]. Sometimes a mediastinal parathyroid adenoma is 
the culprit, but pre-pregnancy SPECT-CT had excluded this in our patient. 
  
Finally, computed tomography (CT) and MRI were not performed because when they 
are used alone they are relatively insensitive in detecting normally located and ectopic 
parathyroid adenomas [12]. In Italy, positron emission tomography (PET) with 
methionine has only recently been proposed for the localization of parathyroid glands, 
and was therefore not performed in our patient before pregnancy. 
 
Considerations on treatment  
Surgery is the first choice of treatment in patients with symptomatic PHPT. Minimally 
invasive approaches have gained progressive acceptance as an alternative safe and 
effective technique over the past two decades, owing to the use preoperative imaging 
to suggest the position of the parathyroid glands [15]. Although negative imaging 
studies would not preclude neck exploration in a young woman with moderately 
severe hypercalcemia and recurrent nephrolithiasis, our patient chose to postpone 
neck exploration with the more invasive techniques required for PTx; medical 
treatment was therefore initiated. However, bone anti-reabsorptive therapy was not 
started because her bones had not been significantly compromised. 
There are no guidelines for the treatment of PHPT in pregnancy. The options are a 
conservative approach or surgery [3]. Both approaches carry the risk of drug related 
side effects and procedure-related side effects, although the risk imposed by 
hypercalcemia is sometimes greater. PTx is the only curative treatment, but is 
recommended only when medical treatment is insufficient [3]. If surgery is deferred, as 
in our case, it should be undertaken as soon as possible after delivery, to prevent a 
hypercalcemic crisis.  
  
Conservative management has been shown to significantly reduce maternal and fetal 
complications [3]. 
Intravenously or orally administered rehydration, with or without forced diuresis, is 
the first line of treatment [11]. 
In our case, we first started hydration without forced diuresis because the patient was 
hypotensive (her mean arterial pressure was 65 to 70 mmHg). However, as saline 
therapy administered intravenously is very unlikely to have a lasting benefit in any 
patient, close maternal and fetal monitoring are necessary in order to prevent clinical 
or biological deterioration. As calcitonin alone is considered ineffective for long-term 
S-Ca control, it was not administered in this case. As bisphosphonates are embryotoxic 
[16], they are not recommended. The use of cinacalcet during pregnancy is debated 
[3]. However, as S-Ca levels were still very high in our patient, cinacalcet seemed the 
best choice. Unfortunately, our case seems to indicate that the use of cinacalcet to 
treat PHPT in pregnancy is not effective in the acute control of S-Ca. In fact, evidence 
for a true benefit of cinacalcet in our case is very weak. Moreover, we do not know 
whether this caused a premature decline in S-Ca or compromised fetal calcium 
metabolism. Before considering cinacalcet treatment, we extensively discussed the 
pros and cons, as its use in pregnancy has been scantly reported. 
 
Review of the literature  
Since the first case of PHPT in pregnancy was reported in 1932 [4], about 200 cases 
have been published in the medical literature. Moreover, only three cases of PHPT in 
  
women on cinacalcet therapy in pregnancy [8, 17, 18] and two cases in puerperium 
[17, 19] have been published. 
Horjus et al. [17] first described a case of PHPT, while Edling et al. [8] described a case 
of parathyromatosis and Nadarasa et al. [18] reported a case of carcinoma. 
In the first two cases, therapy was initiated during the third trimester, whereas in our 
case we decided to start at the end of the second trimester, given the lack of control of 
S-Ca. In the third case, pregnancy was initiated while the patient was on calcium-
lowering therapy, as in our case. In the cases previously reported, tolerance was 
variable, whereas in our case it was poor, thus precluding administration at higher 
doses. In our case, unlike those reported in the literature, it was not possible to 
perform PTx. Therefore, cinacalcet was restarted in the puerperium [17, 19]. 
 
  
Conclusions 
Only three cases of PHPT in women on cinacalcet therapy in pregnancy have been 
published in the medical literature. 
Hydration was useful in controlling S-Ca, and cinacalcet therapy also helped to control 
S-Ca, although it was dangerously high. However, in the present case, evidence for a 
true benefit of cinacalcet is very weak. In our case, cinacalcet tolerance was very poor, 
which precluded the administration of higher doses. It remains unclear whether PTH 
levels in pregnancy were reduced owing to a possible role of placental PTHrP. 
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Table 1: Laboratory findings on diagnosis, during pregnancy, and postpartum 
(median values are reported). 
GFR glomerular filtration rate, Ca(U) urinary calcium, S-Ca serum calcium, S-P serum 
phosphorous, PTH parathyroid hormone, 25OHvitD 25hydroxyvitamin D. 
 
 
 
 
  
Table 2: The time-course of serum calcium and parathyroid hormone levels and 
treatment in a patient with primary hyperparathyroidism. 
i.v. intravenous, NaCl sodium chloride 
 
 
 
 
  
Figure 1: Serum calcium levels in the patient.  
The graph shows the effect of treatments on the patient’s serum calcium levels during 
pregnancy and puerperium. i.v. intravenous, S-Ca serum calcium. 
 
 
 
  
Figure 2: Serum calcium levels in the baby boy.  
The graph shows the effect of treatments on serum ionized calcium levels in the baby 
boy in the first 30 days postpartum. Ca++ ionized calcium. 
 
 
 
 
 
 
 
  
CHAPTER 8 
Conclusions 
 
Minimally invasive techniques have become known in Italy only in recent years. The 
first European papers about LA on benign thyroid nodules dates back to 2000 while 
those about RFA to 2007.  
They were born and were developed in the Korea to remedy the surgery for purely 
aesthetic-cultural reasons (the scars on the neck and on the face are a sign of impurity) 
and then, expanded in Europe because they are effective, safe and more accepted by 
patients than surgery; they are also cheaper than surgery, both total and partial. Since 
2010 the guidelines include RFA e LA among the possible therapies of benign thyroid 
nodules. 
My thesis reports our personal experience in minimally-invasive techniques, RFA e LA, 
in many years of work.  
We perform RFA from January 2012 and we had performed PLA from September 2014 
to December 2015. For a year we were one of few centers in Europe to be able to 
practice both techniques. 
In our work published in 2016 we reported our case studies on 32 benign thyroid 
nodules (between 14 and 76 mL) treated with RFA, performing the procedures 
according to international guidelines.  
Procedures lasted between 2:45 and 15:00 minutes, with a delivery energy between 
349 – 3171 J/ml; the duration of thyroid RFA in our hands was lower than that 
  
reported in the literature and this difference can be ascribed to the personal choice of 
the operator, whose main objective was to prevent severe side effects.  
RFA were preceded by local subcutaneous anaesthesia; in literature is described that 
subcapsular anaesthesia could increase the percentage of adverse events, but no data 
are reported about subcapsular anaesthesia. The volumetric reduction of the nodules 
was -30% a sixth month and -45% at 2 years. There was no significant correlation 
between percentage volume reduction and joules administered during the procedure, 
baseline nodule volume or years since diagnosis. A significant correlation between 
better reduction and patient age was found; we might hypothesize a different 
intracellular content in older patients, which could facilitate necrosis after thyroid RFA. 
In literature, none described this correlation before and none has confirmed this data 
until now.  
Our RFA-treated patients did not have any serious complications during or after the 
procedure (hoarseness, dysphagia, nodule rupture, major bleeding or infections), 
conversely described, albeit rarely in literature; the only reported symptoms were: 
discomfort in the neck, little pain, haematoma and oedema in the neck in the same 
percentage that in literature. These symptoms did not require any kind of medication 
and resolved spontaneously.  
We report, however, a case of thyroid cancer on the track of the electrode 30 months 
after RFA in a 74-year-old woman with negative oncological history and a symptomatic 
multi-nodular goiter with a predominant nodule of 34 mL with two fine-needle 
aspiration biopsy, which revealed a colloid nodular hyperplasia. Thirty months after 
RFA, an ultrasound scan revealed a hypoechoic extra-thyroid jugular median supra-
  
fascial lesion of about 14. FNAB on that lesion showed a hyperplastic, hypercellular 
with focal cytological atypia. The histologic diagnosis of the RFA-treated nodule was of 
a follicular carcinoma with a minority component of papillary carcinoma.  
We suppose that the extra-thyroid lesion was a dissemination of the follicular 
component of the thyroid carcinoma. In conclusion, we suppose that RFA could have 
caused seeding of malignant cells from the nodule. This data is the first reported in 
literature and it needs eventually a confirmation. 
In our paper thyroid functional parameters do not changed after RFA (f-T4 and 
thyroglobulin levels were significantly increased at the first week but they had 
returned to baseline levels by the month-1 follow-up examination). This data are 
similar to data reported in literature and it is one of the reasons why patients often 
prefer minimally invasive technique to surgery. 
As described in literature, 75% of our patients reported an improvement in symptoms 
by means of VAS score. Our patients displayed a significant improvement in VAS at 
follow-up examinations; however, the significance seemed to shrink with time: this 
borderline significance was lost after the 12th month, probably because of the 
decrease in the number of patients at the subsequent time-points of the study.  
In our study, none of the scores on the single ThyPRO scales changed significantly from 
the baseline to the last evaluation. However, the overall score was significantly lower 
at the month-3 evaluation, and this reduction persisted over time.  
To our knowledge, no data on QoL evaluated by means of ThyPRO in patients treated 
with RFA for thyroid nodules have ever been reported.  
We perform LA just for one year in 14 patients with benign nodules from 5 to 55 mL.  
  
LA lasted from 13 to 19 minutes, a time comparable to that reported in literature.  
As for RFA, LA were preceded by local subcutaneous anaesthesia; in literature is 
described that subcapsular anaesthesia could increase the percentage of adverse 
events, but no data are reported about subcapsular anaesthesia. 
After LA, we found a progressive important reduction in nodule volume similar or 
slightly lower than those observed in other centers (-50% at 6th month, -60% at one 
year). At one year, we observed a reduction of > 50% in 86% of the treated patients.  
As in RFA-treated patients, LA-treated patients did not have any serious complications 
during or after the procedure (hoarseness, dysphagia, nodule rupture, major bleeding 
or infections); the only reported symptoms were: discomfort in the neck, little pain, 
haematoma and oedema in the neck, in the same percentage that in literature. These 
symptoms did not require any kind of medication and resolved spontaneously.  
As in RFA and as reported in literature, thyroid functional parameters do not changed 
after LA. 
The VAS score improved in 100% of patients treated with LA. The scale of “goiter 
symptoms” and the scale of “general score” of ThyPRO improved after LA.  
To our knowledge, no data on QoL evaluated by means of ThyPRO in patients treated 
with RFA and LA for thyroid nodules have been reported before; this is the specificity 
of our studies.  
In addition, we participated to an Italian multicenter study of a comparison of laser 
with radiofrequency ablation for the treatment of benign thyroid nodules. In literature 
there are few paper that compare the two techniques. A systematic review tried to 
compare the results of RFA and LA from the data of the published literature; it 
  
concluded that RFA appears to be superior to LA in reducing benign solid thyroid 
nodule volume. A more recent paper compared results of LA and RFA performed by 
the same equip of operators, and found no significant differences among the two 
techniques, suggesting that the two techniques might be similarly effective when 
performed by operators with the same expertise.  
Our work is the first large retrospective cohort study to date which compares safety 
and technique efficacy of RFA and LA in the percutaneous treatment of benign solid 
thyroid nodules by using propensity score matching with power analysis and 
statistically simulating randomized controlled trials.  
This study leads to some interesting considerations: 
1.  both percutaneous thermal ablation procedures were highly effective in 
inducing a significant decrease in thyroid nodule volume; both techniques were 
equally effective in small and medium size nodules (confirmed by propensity 
score adjustment), while the LA showed a slightly greater efficacy than RFA in 
nodules larger than 30 ml (probably due to simultaneous use of multiple laser 
sources in large nodules, with a more homogeneous distribution of heat energy 
in the target area and due to the trans-isthmic approach of RFA that might be 
more difficult to treat the deeper part of large nodules); 
2. the role of the operator experience is determining for the efficacy and the 
extent of nodule volume reduction, regardless of whether laser light or 
radiofrequency energy was used. This problem underscores the importance of 
appropriate training and learning curve; 
  
3. to achieve a comparable volume reduction in small and medium size nodules, 
the operators used more energy (about ten times more) with the 
radiofrequency technique than with laser technology; this data, however, do 
not seem to be relevant in clinical practice because they are inherent to the 
technique used but do not cause the undesired effects on thyroid tissue; 
4. the two procedures appeared both safe and well tolerated, with a similar 
complications rate; 
5. the easiness of use of techniques seems to be subjective and in most cases is 
dependent on the clinical circumstances and on the devices available in the 
institution where the operators work; 
6. taking into account the rental of generators in both techniques, the cost of a 
single laser applicator is about U.S.$250 per session (in most cases two 
applicators are needed) while the cost of an RFA electrode is about U.S.$800 
per session. Both treatments may be performed on outpatients by an operator 
and a nurse. In both procedures, the cost of dressings, including local 
anesthetics and pain-killers, is quite low. 
Finally, we proposed that some patients that don’t respond to RFA can be treated in a 
second chance with LA. Generally, when the first session therapy is not successful, 
another session of the same ablation may be proposed. This choice is probably 
determined by the availability of LA or RFA in each centre. 
In our centre, however, we had the possibility to perform both RFA and LA. We chose 
to perform LA after unsuccessful RFA because in our cohort of patients, we had already 
observed two cases in which the repetition of RFA had failed to yield significant results 
  
in nodules that had previously undergone an unsuccessful RFA procedure. We 
conjectured that certain nodules might be intrinsically resistant to necrosis when one 
ablation technique is undertaken, but might respond to the other ablation technique. 
In our opinion, there are no data in literature about this topic. This data must be 
confirmed with a study in a large cohort of patients. 
From our studies we can conclude that RFA and LA are efficient to reduce the volume 
of benign thyroid nodules and to reduce symptoms at the neck. 
RFA and LA are safe (major adverse events are rare and minor adverse events are 
often asymptomatic and resolve spontaneously). 
RFA and LA do not cause thyroid function alterations in contrast to surgery. 
RFA and LA must be performed by a trained operator, able in minimally invasive 
techniques, to obtain better results and to limit adverse events. 
Follow-up with US-scan is essential to exclude long-term adverse events; in particular, 
we suggest that the regrowth of treated nodule should be followed by a cytological 
examination. 
RFA and LA are cheaper than total and subtotal thyroidectomy and it is very important 
in a period of spending review.  
As suggested by guidelines, minimally invasive techniques should be proposed only to 
patients that have comorbidities that contraindicated surgery or refuse thyroidectomy. 
We agree with guidelines because we think that we can’t produce adverse events, 
even if rare, in treating a benign thyroid nodule and this is the same reason why we 
choose to be less invasive performing RFA and LA, thus obtaining less results in 
nodules reduction than other centres. 
  
More studies are necessary to confirm our data and more studies are necessary to 
understand which nodules can reduce better with RFA or with LA or what nodules will 
not respond, despite more sessions of minimally invasive technique. 
Secondary I participated to the drafting of two papers about primary 
hyperparathyroidism, that was my main interest before 2012 and that was the topic of 
my graduation thesis in 2009. PHPT is a disorder characterized by inappropriately high 
secretion of PTH by an adenoma or a hyperplasia or rarely by a cancer. It is a common 
disease and 80–85% of cases are asymptomatic. 
Therapy may involve medical or surgical treatment: parathyroidectomy is the 
treatment of choice for patients with symptomatic hypercalcemia or evidence of target 
organ damage; conservative management has been favored in asymptomatic patients 
or in some cases surgery fails, in some it is contraindicated, and in others it is refused. 
At the most recent International Workshop, the guidelines pointed out that there was 
no data to support the medical treatment of patients with mild PHPT. In general, it is 
recommended that patients who do not meet surgical criteria be monitored closely. 
However, the validity of medical treatment is unanimously recognized. The prognosis 
of PHPT patients depends on the time-line of the diagnosis. 
In our five-year study, we evaluated 157 patients with PHPT during the course of 
different types of treatment: patients with therapy, patients without therapy and 
patients treated with surgery; moreover, we evaluate QoL in PHPT subjects by means 
of several instruments, both self-rated and physician-administered. 
Half of our patients underwent surgery and, according to literature, a parathyroid 
adenoma in histology was discovered in most cases; as described in literature after 
  
surgery patients have lower levels of PTH and S-Ca than medically-treated group or 
untreated group.  
The untreated group and the bisphosphonate-treated group showed similar reductions 
in S-Ca and PTH concentrations over the five-year follow-up, higher than patients who 
underwent surgery, as reported in literature.  
In the bisphosphonate-treated group, PTH levels tended to remain stable. A slight, 
non-significant increase in PTH levels was found in the untreated group.  
In many patients, PTH concentration remained elevated; these findings are in line with 
those of the literature, although this is usually only seen in 20% of patients or less. It is 
also possible that some of these patients may have been suffering from vitamin D 
deficiency.  
In our study BMD at the spinal level was not significantly different among the three 
groups of subjects, despite bisphosphonates are known to be effective in reducing 
bone turnover in PHPT patients; this data is different from literature that instead 
suggest use of bisphosphonates in PHPT patients with bone impairment. 
In our study, no significant differences in QoL scores emerged among the three groups 
of subjects. In the surgery group, however, QoL improved significantly after 
parathyroidectomy. In semi-structured interviews of 28 subjects, the psychiatric 
evaluation performed did not detect any improvement in psychopathology. In the 
majority of cases in which psychopathology was present, this was minor (anxiety, 
anxiety-depression, reactive depression) and was more frequent in women. 
No significant differences emerged between anti-resorptive therapy and observation 
only.  
  
One obstacle to evaluating illness perception in patients with PHPT is the current lack 
of developed questionnaires in literature.  
Finally, we reported a case of 34-year-old woman with a not-localized PHPT associated 
to hypercalcemia treated with cinacalcet during pregnancy because she refused 
exploratory surgery and calcium levels were not controlled by saline infusion. Only 
three cases of PHPT in women on cinacalcet therapy in pregnancy have been published 
in the medical literature: in two cinacalcet was started in the last trimester, in one it 
was started before, as in our paper. 
In our case the maternal outcome resulted in a preterm delivery at 32nd week of 
pregnancy; the neonatal outcomes were a hyperphosphatemia, hypocalcemia: a 
picture compatible with transitory hypoparathyroidism due to maternal 
hyperparathyroidism with a mild episode of neonatal tetany. In the case described in 
literature there were no adverse maternal outcomes and hypocalcaemia in the 
newborn.  
There are no guidelines for the treatment of PHPT in pregnancy. The options are a 
conservative approach or surgery. Both approaches carry the risk of drug related side 
effects and procedure-related side effects, although the risk imposed by hypercalcemia 
is sometimes greater. Conservative management has been shown to reduce maternal 
and fetal complications. Intravenously or orally administered rehydration, with or 
without forced diuresis, is the first line of treatment, calcitonin alone is considered 
ineffective for long-term S-Ca control and bisphosphonates are embryotoxic. The use 
of cinacalcet during pregnancy is debated but as S-Ca levels in our patient were still 
very high and it seemed the best choice.  
  
Further studies are necessary to understand what are the best therapies to improve 
clinical data and long-term clinical signs of PHPT patients in the reason of the frequent 
mild clinical presentation and, in particular cases, as pregnancy, where is mandatory to 
pondering the risk-benefit. 
